អត្ថបទនេះត្រូវបានសរសេរជាភាសាផ្សេង ដែលមិនមែនជាភាសាខ្មែរ។ បើសិនជាអត្ថបទទុកសម្រាប់អ្នកអានមកពី សហគមន៍នៃភាសាមួយនេះ វាគួរតែចែកចាយទៅវិគីភីឌាជាភាសានោះ។ សូមមើល បញ្ជីនៃគម្រោងវិគីភីឌាទាំងអស់។
សូមមើល ច្រកចូលអត្ថបទនេះ លើក្រុមទំព័រដែលត្រូវការបំណកប្រែទៅជាភាសាខ្មែរ ដើម្បីពិភាក្សា ។ ប្រសិនបើ អត្ថបទមិនត្រូវបានសរសេរជាភាសាខ្មែរឡើងវិញទេ ក្នុងរយៈពេលពីរសប្ដាហ៍ទៀត អត្ថបទនឹងត្រូវចុះបញ្ជីដើម្បីលុបចោល និង/ឬ ប្ដូរវាទៅកាន់វិគីភីឌាជាភាសាដើមរបស់វាវិញ ។
បើសិនជាលោកអ្នក គ្រាន់តែចង់បិទស្លាកទំព័រនេះត្រូវការបំណកប្រែ សូមបញ្ចូល
ទៅខាងក្រោម នៃផ្នែក នៃក្រុមទំព័រនេះត្រូវការបំណកប្រែទៅជាភាសាខ្មែរ ។
|រោគសញ្ញា||ឡើងកម្តៅ, ក្អក, ពិបាកដកដង្ហើម, បាត់បង់ឃានវិញ្ញាណ (ក្លិន)|
|ដង្ហកធ្វើទុក្ខ||រោគរលាកសួត, ពិសឈាមវីរុសviral sepsis, acute respiratory distress syndrome, ការខ្សោយតំរងនោមkidney failure, សមាការព្រលែងកោសិការចលកម្មcytokine release syndrome|
|Usual onset||២–១៤ ថ្ងៃ (ជាធម្មតា ៥) ពីការឆ្លង|
|Risk factors||ធ្វើដំណើរ, ទៅកន្លែងណាដែលងាយប្រថុយនឹងវីរុស|
|Diagnostic method||សំណាក rRT-PCR testing, ការឆ្លុះCT scan|
|Prevention||ការលាងដៃ, បិទមុខ, ចត្តាឡីស័ក (នៅដោយឡែក)|
|Treatment||តាមរោគសញ្ញាSymptomatic និងand ឧបត្ថម្ភsupportive|
|Frequency||១០៤៣៣៣៨៧៨ confirmed cases|
|Deaths||២២៦៥៥៥៩ (២% of confirmed cases)|
ជំងឺកូរ៉ូណាវីរុស២០១៩ (កូវីដ-១៩) គឺជាជំងឺឆ្លងដែលបង្កដោយកូរ៉ូណាវីរុសសមាការផ្លូវដង្ហើមស្រួចស្រាវធ្ងន់ធ្ងរ២ (សារស៍-កូវ-២). កូវីដ-១៩ ត្រូវបានគេរកឃើញដំបូងក្នុងខែធ្នូ ឆ្នាំ២០១៩ នៅក្នុងទីក្រុងអ៊ូហាន, រដ្ឋធានីនៃខេត្តហ៊ូប៉ីរបស់ប្រទេសចិនហើយចាប់តាំងពីពេលនោះមកវាបានរីករាលដាលទៅជុំវិញពិភពលោកហើយបន្តក្លាយជាជំងឺរាតត្បាតសកល។ គិតត្រឹមថ្ងៃ ៤ កុម្ភៈ ២០២១, ករណីប្រមាណ ១០៤ million ករណីត្រូវបានគេរកឃើញនៅតាមប្រទេសនិងដែនដីចំនួន ១៩២ ដែលជាលទ្ធផលមនុស្សប្រមាណជាង ២២៦០០០០ នាក់ត្រូវបានបាត់បង់ជីវិត។ ចំណែកឯអ្នកជាសះស្បើយមានចំនួនជាង ៥៧៩០០០០០ នាក់។
រោគសញ្ញាទូទៅរួមមានគ្រុនក្តៅ, ក្អក, ឆាប់អស់កម្លាំង, ការពិបាកដកដង្ហើម, និងបាត់បង់ឃាណវិញ្ញាណ និងជីវ្ហាវិញ្ញាណ។ រោគសញ្ញានៃករណីកូវីដ-១៩ ភាគច្រើនគឺបែបលក្ខណៈធន់ស្រាល, ប៉ុន្តែខ្លះអាចវិវត្តទៅជារោគរលាកសួត, សរីរាង្គមួយចំនួនឈប់ដំណើរការ, ឫកកសរសៃឈាមជាដើម។ រយៈវេលានៃរោគសញ្ញានឹងចាប់ផ្តើមមាននៅថ្ងៃទីប្រាំបន្ទាប់ពីបានប៉ះជាមួយនឹងវីរុសប៉ុន្តែពេលខ្លះវានឹងចំណាយពេលចាប់ពី ២ ថ្ងៃរហូតដល់ទៅ ១៤ ថ្ងៃឯណោះ។
The virus is primarily spread between people during close contact,[lower-alpha ១] often via small droplets produced by coughing,[lower-alpha ២] sneezing, and talking. The droplets usually fall to the ground or onto surfaces rather than remaining in the air over long distances. People may also become infected by touching a contaminated surface and then touching their face. On surfaces, the amount of virus declines over time until it is insufficient to remain infectious, but it may be detected for hours or days. It is most contagious during the first three days after the onset of symptoms, although spread may be possible before symptoms appear and in later stages of the disease. The standard method of diagnosis is by real-time reverse transcription polymerase chain reaction (rRT-PCR) from a nasopharyngeal swab. Chest CT imaging may also be helpful for diagnosis in individuals where there is a high suspicion of infection based on symptoms and risk factors; however, guidelines do not recommend using it for routine screening.
Recommended measures to prevent infection include frequent hand washing, maintaining physical distance from others (especially from those with symptoms), quarantine, covering coughs, and keeping unwashed hands away from the face. In addition, the use of a face covering is recommended for those who suspect they have the virus and their caregivers. Recommendations for face covering use by the general public vary, with some authorities recommending, some recommending against, and others requiring their use. There is limited evidence for or against the use of masks (medical or other) in healthy individuals in the wider community.
According to the World Health Organization, there are no available vaccines nor specific antiviral treatments for COVID-19. On 1 May 2020, the United States gave Emergency Use Authorization to the antiviral remdesivir for people hospitalized with severe COVID-19. Management involves the treatment of symptoms, supportive care, isolation, and experimental measures. The World Health Organization (WHO) declared the COVID-19 outbreak a Public Health Emergency of International Concern (PHEIC) on 30 January 2020 and a pandemic on 11 March 2020. Local transmission of the disease has occurred in most countries across all six WHO regions.
អាការៈ និង រោគសញ្ញា[កែប្រែ]
|Loss of appetite||40–84%|
|Shortness of breath||31–40%|
|Coughing up sputum||28–33%|
|Muscle aches and pains||11–35%|
Fever is the most common symptom, although some older people and those with other health problems experience fever later in the disease. In one study, 44% of people had fever when they presented to the hospital, while 89% went on to develop fever at some point during their hospitalization.
Other common symptoms include cough, loss of appetite, fatigue, shortness of breath, sputum production, and muscle and joint pains. Symptoms such as nausea, vomiting, and diarrhoea have been observed in varying percentages. Less common symptoms include sneezing, runny nose, or sore throat.
As is common with infections, there is a delay between the moment a person is first infected and the time he or she develops symptoms. This is called the incubation period. The incubation period for COVID‑19 is typically five to six days but may range from two to 14 days, although 97.5% of people who develop symptoms will do so within 11.5 days of infection.
A minority of cases do not develop noticeable symptoms at any point in time. These asymptomatic carriers tend not to get tested, and their role in transmission is not yet fully known. However, preliminary evidence suggests they may contribute to the spread of the disease. In March 2020, the Korea Centers for Disease Control and Prevention (KCDC) reported that 20% of confirmed cases remained asymptomatic during their hospital stay.
In some, the disease may progress to pneumonia, multi-organ failure, and death. Neurological manifestations include [kikilu[seizures]], stroke, encephalitis, and Guillain–Barré syndrome. Cardiovascular-related complications may include heart failure, irregular electrical activity, blood clots, and heart inflammation.
In some people, COVID‑19 may affect the lungs causing pneumonia. In those most severely affected, COVID-19 may rapidly progress to acute respiratory distress syndrome (ARDS) causing respiratory failure, septic shock, or multi-organ failure. Complications associated with COVID‑19 include sepsis, abnormal clotting, and damage to the heart, kidneys, and liver. Clotting abnormalities, specifically an increase in prothrombin time, have been described in 6% of those admitted to hospital with COVID-19, while abnormal kidney function is seen in 4% of this group. Approximately 20-30% of people who present with COVID‑19 demonstrate elevated liver enzymes (transaminases). Liver injury as shown by blood markers of liver damage is frequently seen in severe cases.
COVID-19 is a new disease, and the ways it spreads between people are under investigation, including: the role of small droplets, the extent and how it may be transmitted through air, and how long the virus remains infectious on surfaces. The disease is spread during close contact, often by small droplets produced during coughing, sneezing, or talking. During close contact, (1 to 2 metres, 3 to 6 feet), people catch the disease after breathing in contaminated droplets that were exhaled by infected people. However, the droplets are relatively heavy and usually fall to the ground or surfaces, as opposed to being infectious over large distances.
After the droplets fall to floors or surfaces, they still can infect other people, if they touch contaminated surfaces and then their eyes, nose or mouth with unwashed hands. On surfaces the amount of active virus decreases over time until it can no longer cause infection. However, experimentally, the virus can survive on various surfaces for some time, (for example copper or cardboard for a few hours, and plastic or steel for a few days). Surfaces are easily decontaminated with household disinfectants which kill the virus outside the human body or on the hands. Disinfectants or bleach are not a treatment for COVID-19, and cause health problems when not used properly, such as inside the human body.
Sputum and saliva carry large amounts of virus. Some medical procedures may result in the virus being transmitted easier than normal for such small droplets, known as airborne transmission.
The virus is most contagious during the first three days after onset of symptoms, although spread is known to occur up to two days before symptoms appear (presymptomatic transmission) and in later stages of the disease. Some people have been infected and recovered without showing symptoms, but uncertainties remain in terms of asymptomatic transmission.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel severe acute respiratory syndrome coronavirus, first isolated from three people with pneumonia connected to the cluster of acute respiratory illness cases in Wuhan. All features of the novel SARS-CoV-2 virus occur in related coronaviruses in nature. Outside the human body, the virus is killed by household soap, which bursts its protective bubble.
SARS-CoV-2 is closely related to the original SARS-CoV. It is thought to have a zoonotic origin. Genetic analysis has revealed that the coronavirus genetically clusters with the genus Betacoronavirus, in subgenus Sarbecovirus (lineage B) together with two bat-derived strains. It is 96% identical at the whole genome level to other bat coronavirus samples (BatCov RaTG13). In February 2020, Chinese researchers found that there is only one amino acid difference in the binding domain of the S protein between the coronaviruses from pangolins and those from humans; however, whole-genome comparison to date found that at most 92% of genetic material was shared between pangolin coronavirus and SARS-CoV-2, which is insufficient to prove pangolins to be the intermediate host.
The lungs are the organs most affected by COVID‑19 because the virus accesses host cells via the enzyme angiotensin-converting enzyme 2 (ACE2), which is most abundant in type II alveolar cells of the lungs. The virus uses a special surface glycoprotein called a "spike" (peplomer) to connect to ACE2 and enter the host cell. The density of ACE2 in each tissue correlates with the severity of the disease in that tissue and some have suggested that decreasing ACE2 activity might be protective, though another view is that increasing ACE2 using angiotensin II receptor blocker medications could be protective and these hypotheses need to be tested. As the alveolar disease progresses, respiratory failure might develop and death may follow.
SARS-CoV-2 may also cause respiratory failure through affecting the brainstem as other coronaviruses have been found to invade the central nervous system (CNS). While virus has been detected in cerebrospinal fluid of autopsies, the exact mechanism by which it invades the CNS remains unclear and may first involve invasion of peripheral nerves given the low levels of ACE2 in the brain.
The virus also affects gastrointestinal organs as ACE2 is abundantly expressed in the glandular cells of gastric, duodenal and rectal epithelium as well as endothelial cells and enterocytes of the small intestine.
The virus can cause acute myocardial injury and chronic damage to the cardiovascular system. An acute cardiac injury was found in 12% of infected people admitted to the hospital in Wuhan, China, and is more frequent in severe disease. Rates of cardiovascular symptoms are high, owing to the systemic inflammatory response and immune system disorders during disease progression, but acute myocardial injuries may also be related to ACE2 receptors in the heart. ACE2 receptors are highly expressed in the heart and are involved in heart function. A high incidence of thrombosis (31%) and venous thromboembolism (25%) have been found in ICU patients with COVID‑19 infections and may be related to poor prognosis. Blood vessel dysfunction and clot formation (as suggested by high D-dimer levels) are thought to play a significant role in mortality, incidences of clots leading to pulmonary embolisms, and ischaemic events within the brain have been noted as complications leading to death in patients infected with SARS-CoV-2. Infection appears to set off a chain of vasoconstrictive responses within the body, constriction of blood vessels within the pulmonary circulation has also been posited as a mechanism in which oxygenation decreases alongside the presentation of viral pneumonia.
Another common cause of death is complications related to the kidneys—SARS-CoV-2 directly infects kidney cells, as confirmed in post-mortem studies. Acute kidney injury is a common complication and cause of death; this is more significant in patients with already compromised kidney function, especially in people with pre-existing chronic conditions such as hypertension and diabetes which specifically cause nephropathy in the long run.
Autopsies of people who died of COVID‑19 have found diffuse alveolar damage (DAD), and lymphocyte-containing inflammatory infiltrates within the lung.
Although SARS-COV-2 has a tropism for ACE2-expressing epithelial cells of the respiratory tract, patients with severe COVID‑19 have symptoms of systemic hyperinflammation. Clinical laboratory findings of elevated IL-2, IL-7, IL-6, granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon-γ inducible protein 10 (IP-10), monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1-α (MIP-1α), and tumour necrosis factor-α (TNF-α) indicative of cytokine release syndrome (CRS) suggest an underlying immunopathology.
Additionally, people with COVID‑19 and acute respiratory distress syndrome (ARDS) have classical serum biomarkers of CRS, including elevated C-reactive protein (CRP), lactate dehydrogenase (LDH), D-dimer, and ferritin.
Systemic inflammation results in vasodilation, allowing inflammatory lymphocytic and monocytic infiltration of the lung and the heart. In particular, pathogenic GM-CSF-secreting T-cells were shown to correlate with the recruitment of inflammatory IL-6-secreting monocytes and severe lung pathology in COVID‑19 patients. Lymphocytic infiltrates have also been reported at autopsy.
The WHO has published several testing protocols for the disease. The standard method of testing is real-time reverse transcription polymerase chain reaction (rRT-PCR). The test is typically done on respiratory samples obtained by a nasopharyngeal swab; however, a nasal swab or sputum sample may also be used. Results are generally available within a few hours to two days. Blood tests can be used, but these require two blood samples taken two weeks apart, and the results have little immediate value. Chinese scientists were able to isolate a strain of the coronavirus and publish the genetic sequence so laboratories across the world could independently develop polymerase chain reaction (PCR) tests to detect infection by the virus. កាលពី ថ្ងៃ4 មេសា 2020[update], antibody tests (which may detect active infections and whether a person had been infected in the past) were in development, but not yet widely used. The Chinese experience with testing has shown the accuracy is only 60 to 70%. The FDA in the United States approved the first point-of-care test on 21 March 2020 for use at the end of that month.
Diagnostic guidelines released by Zhongnan Hospital of Wuhan University suggested methods for detecting infections based upon clinical features and epidemiological risk. These involved identifying people who had at least two of the following symptoms in addition to a history of travel to Wuhan or contact with other infected people: fever, imaging features of pneumonia, normal or reduced white blood cell count, or reduced lymphocyte count.
A study asked hospitalised COVID‑19 patients to cough into a sterile container, thus producing a saliva sample, and detected the virus in eleven of twelve patients using RT-PCR. This technique has the potential of being quicker than a swab and involving less risk to health care workers (collection at home or in the car).
Along with laboratory testing, chest CT scans may be helpful to diagnose COVID-19 in individuals with a high clinical suspicion of infection but are not recommended for routine screening. Bilateral multilobar ground-glass opacities with a peripheral, asymmetric, and posterior distribution are common in early infection. Subpleural dominance, crazy paving (lobular septal thickening with variable alveolar filling), and consolidation may appear as the disease progresses.
In late 2019, WHO assigned the emergency ICD-10 disease codes U07.1 for deaths from lab-confirmed SARS-CoV-2 infection and U07.2 for deaths from clinically or epidemiologically diagnosed COVID‑19 without lab-confirmed SARS-CoV-2 infection.
- Macroscopy: pleurisy, pericarditis, lung consolidation and pulmonary oedema
- Four types of severity of viral pneumonia can be observed:
- minor pneumonia: minor serous exudation, minor fibrin exudation
- mild pneumonia: pulmonary oedema, pneumocyte hyperplasia, large atypical pneumocytes, interstitial inflammation with lymphocytic infiltration and multinucleated giant cell formation
- severe pneumonia: diffuse alveolar damage (DAD) with diffuse alveolar exudates. DAD is the cause of acute respiratory distress syndrome (ARDS) and severe hypoxemia.
- healing pneumonia: organisation of exudates in alveolar cavities and pulmonary interstitial fibrosis
- plasmocytosis in BAL
- Blood: disseminated intravascular coagulation (DIC); leukoerythroblastic reaction
- Liver: microvesicular steatosis
Preventive measures to reduce the chances of infection include staying at home, avoiding crowded places, keeping distance from others, washing hands with soap and water often and for at least 20 seconds, practising good respiratory hygiene, and avoiding touching the eyes, nose, or mouth with unwashed hands. The CDC recommends covering the mouth and nose with a tissue when coughing or sneezing and recommends using the inside of the elbow if no tissue is available. Proper hand hygiene after any cough or sneeze is encouraged. The CDC has recommended the use of cloth face coverings in public settings where other social distancing measures are difficult to maintain, in part to limit transmission by asymptomatic individuals. The U.S. National Institutes of Health guidelines do not recommend any medication for prevention of COVID‑19, before or after exposure to the SARS-CoV-2 virus, outside of the setting of a clinical trial.
Social distancing strategies aim to reduce contact of infected persons with large groups by closing schools and workplaces, restricting travel, and cancelling large public gatherings. Distancing guidelines also include that people stay at least 6 feet (1.8 m) apart. There is no medication known to be effective at preventing COVID‑19. After the implementation of social distancing and stay-at-home orders, many regions have been able to sustain an effective transmission rate ("Rt") of less than one, meaning the disease is in remission in those areas. In a simple model needs on average over time be kept at or below zero to avoid exponential growth.[ត្រូវការអំណះអំណាង]
As a vaccine is not expected until 2021 at the earliest, a key part of managing COVID‑19 is trying to decrease and delay the epidemic peak, known as "flattening the curve". This is done by slowing the infection rate to decrease the risk of health services being overwhelmed, allowing for better treatment of current cases, and delaying additional cases until effective treatments or a vaccine become available.
According to the WHO, the use of masks is recommended only if a person is coughing or sneezing or when one is taking care of someone with a suspected infection. For the European Centre for Disease Prevention and Control (ECDC) face masks "... could be considered especially when visiting busy closed spaces ..." but "... only as a complementary measure ..." Several countries have recommended that healthy individuals wear face masks or cloth face coverings (like scarves or bandanas) at least in certain public settings, including China, Hong Kong, Spain, Italy (Lombardy region), Russia, and the United States.
Those diagnosed with COVID‑19 or who believe they may be infected are advised by the CDC to stay home except to get medical care, call ahead before visiting a healthcare provider, wear a face mask before entering the healthcare provider's office and when in any room or vehicle with another person, cover coughs and sneezes with a tissue, regularly wash hands with soap and water and avoid sharing personal household items. The CDC also recommends that individuals wash hands often with soap and water for at least 20 seconds, especially after going to the toilet or when hands are visibly dirty, before eating and after blowing one's nose, coughing or sneezing. It further recommends using an alcohol-based hand sanitiser with at least 60% alcohol, but only when soap and water are not readily available.
For areas where commercial hand sanitisers are not readily available, the WHO provides two formulations for local production. In these formulations, the antimicrobial activity arises from ethanol or isopropanol. Hydrogen peroxide is used to help eliminate bacterial spores in the alcohol; it is "not an active substance for hand antisepsis". Glycerol is added as a humectant.
People are managed with supportive care, which may include fluid therapy, oxygen support, and supporting other affected vital organs. The CDC recommends that those who suspect they carry the virus wear a simple face mask. Extracorporeal membrane oxygenation (ECMO) has been used to address the issue of respiratory failure, but its benefits are still under consideration. Personal hygiene and a healthy lifestyle and diet have been recommended to improve immunity. Supportive treatments may be useful in those with mild symptoms at the early stage of infection.
The WHO, the Chinese National Health Commission, and the United States' National Institutes of Health have published recommendations for taking care of people who are hospitalised with COVID‑19. Intensivists and pulmonologists in the U.S. have compiled treatment recommendations from various agencies into a free resource, the IBCC.
Per the World Health Organization, as of April 2020, there is no specific treatment for COVID‑19. On May 1, 2020, the United States gave Emergency Use Authorization (not full approval) for remdesivir in people hospitalized with severe COVID-19 after a study suggested it reduced the duration of recovery. Researchers continue working on more effective treatments and many vaccine candidates are in development or testing phases.
For symptoms, some medical professionals recommend paracetamol (acetaminophen) over ibuprofen for first-line use. The WHO and NIH do not oppose the use of non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen for symptoms, and the FDA says currently there is no evidence that NSAIDs worsen COVID‑19 symptoms.
While theoretical concerns have been raised about ACE inhibitors and angiotensin receptor blockers, as of 19 March 2020, these are not sufficient to justify stopping these medications. One study from April 22 found that people with COVID-19 and hypertension had lower all-cause mortality when on these medications.
The Australasian Society of Clinical Immunology and Allergy recommend that tocilizumab should be considered as an off-label treatment option for those with COVID-19 related acute respiratory distress syndrome. It recommends this because of its known benefit in cytokine storm caused by a specific cancer treatment, and that cytokine storm may be a significant contributor to mortality in severe COVID-19.
Medications to prevent blood clotting have been suggested for treatment, and anticoagulant therapy with low molecular weight heparin appears to be associated with better outcomes in severe COVID‐19 showing signs of coagulopathy (elevated D-dimer).
Precautions must be taken to minimise the risk of virus transmission, especially in healthcare settings when performing procedures that can generate aerosols, such as intubation or hand ventilation. For healthcare professionals caring for people with COVID‑19, the CDC recommends placing the person in an Airborne Infection Isolation Room (AIIR) in addition to using standard precautions, contact precautions, and airborne precautions.
The CDC outlines the guidelines for the use of personal protective equipment (PPE) during the pandemic. The recommended gear is a PPE gown, respirator or facemask, eye protection, and medical gloves.
When available, respirators (instead of facemasks) are preferred. N95 respirators are approved for industrial settings but the FDA has authorised the masks for use under an Emergency Use Authorisation (EUA). They are designed to protect from airborne particles like dust but effectiveness against a specific biological agent is not guaranteed for off-label uses. When masks are not available, the CDC recommends using face shields or, as a last resort, homemade masks.
Most cases of COVID‑19 are not severe enough to require mechanical ventilation or alternatives, but a percentage of cases are. The type of respiratory support for individuals with COVID‑19 related respiratory failure is being actively studied for people in the hospital, with some evidence that intubation can be avoided with a high flow nasal cannula or bi-level positive airway pressure. Whether either of these two leads to the same benefit for people who are critically ill is not known. Some doctors prefer staying with invasive mechanical ventilation when available because this technique limits the spread of aerosol particles compared to a high flow nasal cannula.
Severe cases are most common in older adults (those older than 60 years, and especially those older than 80 years). Many developed countries do not have enough hospital beds per capita, which limits a health system's capacity to handle a sudden spike in the number of COVID‑19 cases severe enough to require hospitalisation. This limited capacity is a significant driver behind calls to flatten the curve. One study in China found 5% were admitted to intensive care units, 2.3% needed mechanical support of ventilation, and 1.4% died. In China, approximately 30% of people in hospital with COVID‑19 are eventually admitted to ICU.
Acute respiratory distress syndrome[កែប្រែ]
Mechanical ventilation becomes more complex as acute respiratory distress syndrome (ARDS) develops in COVID‑19 and oxygenation becomes increasingly difficult. Ventilators capable of pressure control modes and high PEEP are needed to maximise oxygen delivery while minimising the risk of ventilator-associated lung injury and pneumothorax. High PEEP may not be available on older ventilators.[ត្រូវការអំណះអំណាង]
|High-flow nasal oxygen||For SpO2 <93%. May prevent the need for intubation and ventilation|
|Tidal volume||6mL per kg and can be reduced to 4mL/kg|
|Plateau airway pressure||Keep below 30 cmH2O if possible (high respiratory rate (35 per minute) may be required)|
|Positive end-expiratory pressure||Moderate to high levels|
|Prone positioning||For worsening oxygenation|
|Fluid management||Goal is a negative balance of 0.5–1.0L per day|
|Antibiotics||For secondary bacterial infections|
Research into potential treatments started in January 2020, and several antiviral drugs are in clinical trials. Remdesivir appears to be the most promising. Although new medications may take until 2021 to develop, several of the medications being tested are already approved for other uses or are already in advanced testing. Antiviral medication may be tried in people with severe disease. The WHO recommended volunteers take part in trials of the effectiveness and safety of potential treatments.
The FDA has granted temporary authorisation to convalescent plasma as an experimental treatment in cases where the person's life is seriously or immediately threatened. It has not undergone the clinical studies needed to show it is safe and effective for the disease.
In February 2020, China launched a mobile app to deal with the disease outbreak. Users are asked to enter their name and ID number. The app can detect 'close contact' using surveillance data and therefore a potential risk of infection. Every user can also check the status of three other users. If a potential risk is detected, the app not only recommends self-quarantine, it also alerts local health officials.
Big data analytics on cellphone data, facial recognition technology, mobile phone tracking, and artificial intelligence are used to track infected people and people whom they contacted in South Korea, Taiwan, and Singapore. In March 2020, the Israeli government enabled security agencies to track mobile phone data of people supposed to have coronavirus. The measure was taken to enforce quarantine and protect those who may come into contact with infected citizens. Also in March 2020, Deutsche Telekom shared aggregated phone location data with the German federal government agency, Robert Koch Institute, to research and prevent the spread of the virus. Russia deployed facial recognition technology to detect quarantine breakers. Italian regional health commissioner Giulio Gallera said he has been informed by mobile phone operators that "40% of people are continuing to move around anyway". German government conducted a 48 hours weekend hackathon with more than 42.000 participants. Two million people in the UK used an app developed in March 2020 by King's College London and Zoe to track people with COVID‑19 symptoms. Also, the president of Estonia, Kersti Kaljulaid, made a global call for creative solutions against the spread of coronavirus.
Individuals may experience distress from quarantine, travel restrictions, side effects of treatment, or fear of the infection itself. To address these concerns, the National Health Commission of China published a national guideline for psychological crisis intervention on 27 January 2020.
The Lancet published a 14-page call for action focusing on the UK and stated conditions were such that a range of mental health issues was likely to become more common. BBC quoted Rory O'Connor in saying, "Increased social isolation, loneliness, health anxiety, stress, and an economic downturn are a perfect storm to harm people's mental health and wellbeing."
|This article relies on references to primary sources or sources affiliated with the subject, rather than references from independent authors and third-party publications. Please add more appropriate citations from reliable sources. (March 2020)|
The severity of COVID‑19 varies. The disease may take a mild course with few or no symptoms, resembling other common upper respiratory diseases such as the common cold. Mild cases typically recover within two weeks, while those with severe or critical diseases may take three to six weeks to recover. Among those who have died, the time from symptom onset to death has ranged from two to eight weeks.
Children make up a small proportion of reported cases, with about 1% of cases being under 10 years and 4% aged 10–19 years. They are likely to have milder symptoms and a lower chance of severe disease than adults; in those younger than 50 years the risk of death is less than 0.5%, while in those older than 70 it is more than 8%. Pregnant women may be at higher risk for severe infection with COVID-19 based on data from other similar viruses, like SARS and MERS, but data for COVID-19 is lacking. In China, children acquired infections mainly through close contact with their parents or other family members who lived in Wuhan or had traveled there.
Most of those who die of COVID‑19 have pre-existing (underlying) conditions, including hypertension, diabetes mellitus, and cardiovascular disease. The Istituto Superiore di Sanità reported that out of 8.8% of deaths where medical charts were available for review, 97.2% of sampled patients had at least one comorbidity with the average patient having 2.7 diseases. According to the same report, the median time between the onset of symptoms and death was ten days, with five being spent hospitalised. However, patients transferred to an ICU had a median time of seven days between hospitalisation and death. In a study of early cases, the median time from exhibiting initial symptoms to death was 14 days, with a full range of six to 41 days. In a study by the National Health Commission (NHC) of China, men had a death rate of 2.8% while women had a death rate of 1.7%. Histopathological examinations of post-mortem lung samples show diffuse alveolar damage with cellular fibromyxoid exudates in both lungs. Viral cytopathic changes were observed in the pneumocytes. The lung picture resembled acute respiratory distress syndrome (ARDS). In 11.8% of the deaths reported by the National Health Commission of China, heart damage was noted by elevated levels of troponin or cardiac arrest. According to March data from the United States, 89% of those hospitalised had preexisting conditions.
The availability of medical resources and the socioeconomics of a region may also affect mortality. Estimates of the mortality from the condition vary because of those regional differences, but also because of methodological difficulties. The under-counting of mild cases can cause the mortality rate to be overestimated. However, the fact that deaths are the result of cases contracted in the past can mean the current mortality rate is underestimated. Smokers were 1.4 times more likely to have severe symptoms of COVID‑19 and approximately 2.4 times more likely to require intensive care or die compared to non-smokers.
Concerns have been raised about long-term sequelae of the disease. The Hong Kong Hospital Authority found a drop of 20% to 30% in lung capacity in some people who recovered from the disease, and lung scans suggested organ damage. This may also lead to post-intensive care syndrome following recovery.
|United States as of 16 March||0.0||0.1–0.2||0.5–0.8||1.4–2.6||2.7–4.9||4.3–10.5||10.4–27.3|
|Note: The lower bound includes all cases. The upper bound excludes cases that were missing data.|
|Total infection fatality rate is estimated to be 0.66% (0.39–1.3). Infection fatality rate is fatality per all infected individuals, regardless of whether they were diagnosed or had any symptoms. Numbers in parentheses are 95% credible intervals for the estimates.|
It is unknown (as of April 2020) if past infection provides effective and long-term immunity in people who recover from the disease. Some of the infected have been reported to develop protective antibodies, so acquired immunity is presumed likely, based on the behaviour of other coronaviruses. However, cases in which recovery from COVID‑19 was followed by positive tests for coronavirus at a later date have been reported. These cases are believed to be lingering infection rather than reinfection, or false positives due to remaining RNA fragments. Some other coronaviruses circulating in people are capable of reinfection after roughly a year.
The virus is thought to be natural and has an animal origin, through spillover infection. The actual origin is unknown, but the first known cases of infection happened in China. By December 2019, the spread of infection was almost entirely driven by human-to-human transmission. A study of the first 41 cases of confirmed COVID‑19, published in January 2020 in The Lancet, revealed the earliest date of onset of symptoms as 1 December 2019. Official publications from the WHO reported the earliest onset of symptoms as 8 December 2019. Human-to-human transmission was confirmed by the WHO and Chinese authorities by 20 January 2020.
Several measures are commonly used to quantify mortality. These numbers vary by region and over time and are influenced by the volume of testing, healthcare system quality, treatment options, time since the initial outbreak, and population characteristics such as age, sex, and overall health.
The death-to-case ratio reflects the number of deaths divided by the number of diagnosed cases within a given time interval. Based on Johns Hopkins University statistics, the global death-to-case ratio is  The number varies by region.២% (២២៦៥៥៥៩/១០៤៣៣៣៨៧៨) as of ៤ កុម្ភៈ ២០២១.
Other measures include the case fatality rate (CFR), which reflects the percent of diagnosed individuals who die from a disease, and the infection fatality rate (IFR), which reflects the percent of infected individuals (diagnosed and undiagnosed) who die from a disease. These statistics are not time-bound and follow a specific population from infection through case resolution. Many academics have attempted to calculate these numbers for specific populations.
Outbreaks have occurred in prisons due to crowding and an inability to enforce adequate social distancing. In the United States, the prisoner population is aging and many of them are at high risk for poor outcomes from COVID-19 due to high rates of coexisting heart and lung disease, and poor access to high-quality healthcare.
Infection fatality rate[កែប្រែ]
Our World in Data states that as of March 25, 2020, the infection fatality rate (IFR) cannot be accurately calculated. In February, the World Health Organization estimated the IFR at 0.94%, with a confidence interval between 0.37 percent to 2.9 percent. The University of Oxford Centre for Evidence-Based Medicine (CEBM) estimated a global CFR of 0.72 percent and IFR of 0.1 percent to 0.36 percent. According to CEBM, random antibody testing in Germany suggested an IFR of 0.37% (0.12% to 0.87%) there, but there have been concerns about false positives. Firm lower limits of infection fatality rates have been established in a number of locations. In New York City, with a population of 8.4 million, as of April 25, 16,673 (0.20% of the population) have died from COVID-19, and 20,800 (0.25% of the population) excess deaths have occurred, and in Bergamo province, where 0.57% of the population has died. To get a better view on the number of people infected initial antibody testing have been carried out, but there are no valid scientific reports based on any of them as of yet.
The impact of the pandemic and its mortality rate are different for men and women. Mortality is higher in men in studies conducted in China and Italy. The higher risk for men appears in their 50s, and begins to taper off only at 90. In China, the death rate was 2.8 percent for men and 1.7 percent for women. The exact reasons for this sex-difference are not known, but genetic and behavioural factors could be a reason. Sex-based immunological differences, a lower prevalence of smoking in women, and men developing co-morbid conditions such as hypertension at a younger age than women could have contributed to the higher mortality in men. In Europe, of those infected with COVID‑19, 57% were men; of those infected with COVID‑19 who also died, 72% were men. As of April 2020, the U.S. government is not tracking sex-related data of COVID‑19 infections. Research has shown that viral illnesses like Ebola, HIV, influenza, and SARS affect men and women differently. A higher percentage of health workers, particularly nurses, are women, and they have a higher chance of being exposed to the virus. School closures, lockdowns, and reduced access to healthcare following the 2019–20 coronavirus pandemic may differentially affect the genders and possibly exaggerate existing gender disparity.
In the U.S., a greater proportion of deaths due to COVID-19 have occurred among African Americans. Structural factors that prevent African Americans from practicing social distancing include their concentration in crowded substandard housing and "essential" occupations such as public transit employees and health-care workers. Greater prevalence of lacking health insurance and care and of underlying conditions such as diabetes, hypertension and heart disease also increase their risk of death. Similar issues affect Native American and Latino communities. Leaders have called for efforts to research and address the disparities.
Existing respiratory problems[កែប្រែ]
When someone with existing respiratory problems is infected with COVID-19, they are at greater risk for severe symptoms. COVID-19 also poses a greater risk to people who misuse opioids and methamphetamines, insofar as their drug use may have caused lung damage.
សង្គម និង វប្បធម៌[កែប្រែ]
During the initial outbreak in Wuhan, China, the virus and disease were commonly referred to as "coronavirus" and "Wuhan coronavirus", with the disease sometimes called "Wuhan pneumonia". In the past, many diseases have been named after geographical locations, such as the Spanish flu, Middle East Respiratory Syndrome, and Zika virus.
In January 2020, the World Health Organisation recommended 2019-nCov and 2019-nCoV acute respiratory disease as interim names for the virus and disease per 2015 guidance and international guidelines against using geographical locations (e.g. Wuhan, China), animal species or groups of people in disease and virus names to prevent social stigma.
The official names COVID‑19 and SARS-CoV-2 were issued by the WHO on 11 February 2020. WHO chief Tedros Adhanom Ghebreyesus explained: CO for corona, VI for virus, D for disease and 19 for when the outbreak was first identified (31 December 2019). The WHO additionally uses "the COVID‑19 virus" and "the virus responsible for COVID‑19" in public communications. Both the disease and virus are commonly referred to as "coronavirus" in the media and public discourse.
After the initial outbreak of COVID‑19, conspiracy theories, misinformation and disinformation emerged regarding the origin, scale, prevention, treatment and other aspects of the disease and rapidly spread online.
Decreased emergency room use[កែប្រែ]
In Austria, 39% fewer persons sought help for cardiac symptoms in the month of March. A study estimated that there were 110 incidents of preventable cardiac death as compared to 86 confirmed deaths from Coronavirus as of March 29.
A preliminary study in the U.S. found 38% under-utilization of cardiac care units as compared to normal. The head of cardiology at the University of Arizona has stated, "My worry is some of these people are dying at home because they're too scared to go to the hospital." There is also concern that persons with symptoms of stroke and appendicitis are delaying seeking help.
Humans appear to be capable of spreading the virus to some other animals. A domestic cat in Liège, Belgium, tested positive after it started showing symptoms (diarrhoea, vomiting, shortness of breath) a week later than its owner, who was also positive. Tigers at the Bronx Zoo in New York, United States, tested positive for the virus and showed symptoms of COVID‑19, including a dry cough and loss of appetite. Minks at two farms in the Netherlands also tested positive for COVID-19.
A study on domesticated animals inoculated with the virus found that cats and ferrets appear to be "highly susceptible" to the disease, while dogs appear to be less susceptible, with lower levels of viral replication. The study failed to find evidence of viral replication in pigs, ducks, and chickens.
No medication or vaccine is approved to treat the disease. International research on vaccines and medicines in COVID‑19 is underway by government organisations, academic groups, and industry researchers. In March, the World Health Organisation initiated the "SOLIDARITY Trial" to assess the treatment effects of four existing antiviral compounds with the most promise of efficacy.
There has been a great deal of COVID-19 research, involving accelerated research processes and publishing shortcuts to meet the global demand. To minimise the impact of misinformation, medical professionals and the public are advised to expect rapid changes to available information, and to be attentive to retractions and other updates.
There is no available vaccine, but various agencies are actively developing vaccine candidates. Previous work on SARS-CoV is being used because both SARS-CoV and SARS-CoV-2 use the ACE2 receptor to enter human cells. Three vaccination strategies are being investigated. First, researchers aim to build a whole virus vaccine. The use of such a virus, be it inactive or dead, aims to elicit a prompt immune response of the human body to a new infection with COVID‑19. A second strategy, subunit vaccines, aims to create a vaccine that sensitises the immune system to certain subunits of the virus. In the case of SARS-CoV-2, such research focuses on the S-spike protein that helps the virus intrude the ACE2 enzyme receptor. A third strategy is that of the nucleic acid vaccines (DNA or RNA vaccines, a novel technique for creating a vaccination). Experimental vaccines from any of these strategies would have to be tested for safety and efficacy.
On 16 March 2020, the first clinical trial of a vaccine started with four volunteers in Seattle, United States. The vaccine contains a harmless genetic code copied from the virus that causes the disease.
At least 29 phase II–IV efficacy trials in COVID‑19 were concluded in March 2020 or scheduled to provide results in April from hospitals in China. There are more than 300 active clinical trials underway as of April 2020. Seven trials were evaluating already approved treatments, including four studies on hydroxychloroquine or chloroquine. Repurposed antiviral drugs make up most of the Chinese research, with nine phase III trials on remdesivir across several countries due to report by the end of April. Other candidates in trials include vasodilators, corticosteroids, immune therapies, lipoic acid, bevacizumab, and recombinant angiotensin-converting enzyme 2.
The COVID‑19 Clinical Research Coalition has goals to 1) facilitate rapid reviews of clinical trial proposals by ethics committees and national regulatory agencies, 2) fast-track approvals for the candidate therapeutic compounds, 3) ensure standardised and rapid analysis of emerging efficacy and safety data and 4) facilitate sharing of clinical trial outcomes before publication.
Several existing medications are being evaluated for the treatment of COVID‑19, including remdesivir, chloroquine, hydroxychloroquine, lopinavir/ritonavir, and lopinavir/ritonavir combined with interferon beta. There is tentative evidence for efficacy by remdesivir, as of March 2020. Clinical improvement was observed in patients treated with compassionate-use remdesivir. Remdesivir inhibits SARS-CoV-2 in vitro. Phase III clinical trials are underway in the U.S., China, and Italy.
In 2020, a trial found that lopinavir/ritonavir was ineffective in the treatment of severe illness. Nitazoxanide has been recommended for further in vivo study after demonstrating low concentration inhibition of SARS-CoV-2.
There are mixed results as of 3 April 2020 as to the effectiveness of hydroxychloroquine as a treatment for COVID‑19, with some studies showing little or no improvement. The studies of chloroquine and hydroxychloroquine with or without azithromycin have major limitations that have prevented the medical community from embracing these therapies without further study.
Tocilizumab has been included in treatment guidelines by China's National Health Commission after a small study was completed. It is undergoing a phase 2 non-randomised trial at the national level in Italy after showing positive results in people with severe disease. Combined with a serum ferritin blood test to identify cytokine storms, it is meant to counter such developments, which are thought to be the cause of death in some affected people. The interleukin-6 receptor antagonist was approved by the FDA to undergo a phase III clinical trial assessing the medication's impact on COVID‑19 based on retrospective case studies for the treatment of steroid-refractory cytokine release syndrome induced by a different cause, CAR T cell therapy, in 2017. To date, there is no randomised, controlled evidence that tocilizumab is an efficacious treatment for CRS. Prophylactic tocilizumab has been shown to increase serum IL-6 levels by saturating the IL-6R, driving IL-6 across the blood-brain barrier, and exacerbating neurotoxicity while having no impact on the incidence of CRS.
Lenzilumab, an anti-GM-CSF monoclonal antibody, is protective in murine models for CAR T cell-induced CRS and neurotoxicity and is a viable therapeutic option due to the observed increase of pathogenic GM-CSF secreting T-cells in hospitalised patients with COVID‑19.
Transferring purified and concentrated antibodies produced by the immune systems of those who have recovered from COVID‑19 to people who need them is being investigated as a non-vaccine method of passive immunisation. This strategy was tried for SARS with inconclusive results. Viral neutralisation is the anticipated mechanism of action by which passive antibody therapy can mediate defence against SARS-CoV-2. Other mechanisms, however, such as antibody-dependent cellular cytotoxicity and/or phagocytosis, may be possible. Other forms of passive antibody therapy, for example, using manufactured monoclonal antibodies, are in development. Production of convalescent serum, which consists of the liquid portion of the blood from recovered patients and contains antibodies specific to this virus, could be increased for quicker deployment.
- Coronavirus diseases, a group of closely related syndromes
- Coronavirus recession
- Disease X, a WHO term
- Li Wenliang, a doctor at Central Hospital of Wuhan who died of COVID-19 after raising awareness of its spread
- List of unproven methods against COVID-19
Lua error in package.lua at line 80: module 'Module:Portal/images/m' not found.
- Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L (កុម្ភៈ 2020) "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study" Lancet 395 (10223): 507–513 doi:10.1016/S0140-6736(20)30211-7 PMC 7135076 Check
|pmc=value (ជំនួយ) PMID 32007143 Check
- Han X, Cao Y, Jiang N, Chen Y, Alwalid O, Zhang X, et al. (មីនា 2020) "Novel Coronavirus Pneumonia (COVID-19) Progression Course in 17 Discharged Patients: Comparison of Clinical and Thin-Section CT Features During Recovery" Clinical Infectious Diseases doi:10.1093/cid/ciaa271 PMC 7184369 Check
|pmc=value (ជំនួយ) PMID 32227091 Check
- "Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19)" Centers for Disease Control and Prevention 6 មេសា 2020 បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ2 មីនា 2020 ដកស្រង់នៅថ្ងៃ 19 មេសា 2020 Unknown parameter
- "Symptoms of Coronavirus" U.S. Centers for Disease Control and Prevention (CDC) 20 មីនា 2020 បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ30 មករា 2020 Unknown parameter
- "Q&A on coronaviruses" World Health Organization 8 មេសា 2020 បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ20 មករា 2020 ដកស្រង់នៅថ្ងៃ 30 មេសា 2020 Unknown parameter
- Nussbaumer-Streit, B; Mayr, V; Dobrescu, AI; Chapman, A; Persad, E; Klerings, I; Wagner, G; Siebert, U; Christof, C; Zachariah, C; Gartlehner, G (8 មេសា 2020) "Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review." The Cochrane Database of Systematic Reviews 4: CD013574 doi:10.1002/14651858.CD013574 PMC 7141753 Check
|pmc=value (ជំនួយ) PMID 32267544 Check
- "COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU)" ArcGIS Johns Hopkins University ដកស្រង់នៅថ្ងៃ 23 មេសា 2020
- "Coronavirus disease 2019 (COVID-19)—Symptoms and causes" Mayo Clinic ដកស្រង់នៅថ្ងៃ 14 មេសា 2020
- Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, et al. (កុម្ភៈ 2020) "The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China" Int J Infect Dis 91: 264–66 doi:10.1016/j.ijid.2020.01.009 PMC 7128332 Check
|pmc=value (ជំនួយ) PMID 31953166
- "WHO Director-General's opening remarks at the media briefing on COVID-19"។ Press release។ 11 March 2020។ https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020។ បានយកមក 12 March 2020។
- "Q&A on coronaviruses (COVID-19)" World Health Organization (WHO) បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ20 មករា 2020 ដកស្រង់នៅថ្ងៃ 11 មីនា 2020 Unknown parameter
- Hopkins, Claire "Loss of sense of smell as marker of COVID-19 infection" Ear, Nose and Throat surgery body of United Kingdom ដកស្រង់នៅថ្ងៃ 28 មីនា 2020
- Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ (មីនា 2020) "COVID-19: consider cytokine storm syndromes and immunosuppression" Lancet 395 (10229): 1033–1034 doi:10.1016/S0140-6736(20)30628-0 PMID 32192578 Check
- "Q&A on coronaviruses" World Health Organization (WHO) បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ20 មករា 2020 ដកស្រង់នៅថ្ងៃ 27 មករា 2020 Unknown parameter
- Velavan, T. P.; Meyer, C. G. (មីនា 2020) "The COVID-19 epidemic" Tropical Medicine & International Health n/a (n/a): 278–80 doi:10.1111/tmi.13383 PMC 7169770 Check
|pmc=value (ជំនួយ) PMID 32052514 Check
- "How COVID-19 Spreads" Centers for Disease Control and Prevention (CDC) 2 មេសា 2020 បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ3 មេសា 2020 ដកស្រង់នៅថ្ងៃ 3 មេសា 2020 Unknown parameter
- Bourouiba L (មីនា 2020) "Turbulent Gas Clouds and Respiratory Pathogen Emissions: Potential Implications for Reducing Transmission of COVID-19" JAMA doi:10.1001/jama.2020.4756 PMID 32215590 Check
- "Q & A on COVID-19" European Centre for Disease Prevention and Control ដកស្រង់នៅថ្ងៃ 30 មេសា 2020
- "New coronavirus stable for hours on surfaces" National Institutes of Health 17 មីនា 2020 បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ23 មីនា 2020 ដកស្រង់នៅថ្ងៃ 30 មេសា 2020 Unknown parameter
- "Coronavirus disease 2019 (COVID-19) Situation Report—73" (PDF) World Health Organization 2 មេសា 2020 ដកស្រង់នៅថ្ងៃ 3 មេសា 2020 Unknown parameter
- "Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease 2019 (COVID-19)" Centers for Disease Control and Prevention (CDC) 11 កុម្ភៈ 2020 បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ4 មីនា 2020 ដកស្រង់នៅថ្ងៃ 26 មីនា 2020 Unknown parameter
- Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A (មីនា 2020) "Coronavirus Disease 2019 (COVID-19): A Systematic Review of Imaging Findings in 919 Patients" American Journal of Roentgenology: 1–7 doi:10.2214/AJR.20.23034 PMID 32174129 Check
- "ACR Recommendations for the use of Chest Radiography and Computed Tomography (CT) for Suspected COVID-19 Infection" American College of Radiology 22 មីនា 2020 បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ28 មីនា 2020 Unknown parameter
- "Advice for public" World Health Organization (WHO) បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ26 មករា 2020 ដកស្រង់នៅថ្ងៃ 25 កុម្ភៈ 2020 Unknown parameter
- "Guidance on social distancing for everyone in the UK" GOV.UK បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ24 មីនា 2020 ដកស្រង់នៅថ្ងៃ 25 មីនា 2020 Unknown parameter
- Centers for Disease Control and Prevention (5 មេសា 2020) "What to Do if You Are Sick" Centers for Disease Control and Prevention (CDC) បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ14 កុម្ភៈ 2020 ដកស្រង់នៅថ្ងៃ 24 មេសា 2020 Unknown parameter
- "When and how to use masks" World Health Organization (WHO) បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ7 មីនា 2020 ដកស្រង់នៅថ្ងៃ 24 មេសា 2020 Unknown parameter
- Feng S, Shen C, Xia N, Song W, Fan M, Cowling BJ (មីនា 2020) "Rational use of face masks in the COVID-19 pandemic" Lancet Respiratory Medicine 0 (5): 434–436 doi:10.1016/S2213-2600(20)30134-X PMC 7118603 Check
|pmc=value (ជំនួយ) PMID 32203710 Check
- Tait, Robert (30 មីនា 2020) "Czechs get to work making masks after government decree" The Guardian ISSN 0261-3077 បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ30 មីនា 2020 ដកស្រង់នៅថ្ងៃ 31 មីនា 2020 Unknown parameter
- "Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment"។ Press release។ 1 May 2020។ https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment។ បានយកមក 1 May 2020។
- "How to Protect Yourself & Others" Centers for Disease Control and Prevention (CDC) 8 មេសា 2020 បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ26 កុម្ភៈ 2020 ដកស្រង់នៅថ្ងៃ 9 មេសា 2020 Unknown parameter
- "Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV)" World Health Organization (WHO) បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ31 មករា 2020 ដកស្រង់នៅថ្ងៃ 11 កុម្ភៈ 2020 Unknown parameter
- Mahtani S, Berger M, O'Grady S, Iati M (6 កុម្ភៈ 2020) "Hundreds of evacuees to be held on bases in California; Hong Kong and Taiwan restrict travel from mainland China" The Washington Post បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ7 កុម្ភៈ 2020 ដកស្រង់នៅថ្ងៃ 11 កុម្ភៈ 2020 Unknown parameter
- "WHO Situation Report #87" (PDF) WHO 16 មេសា 2020 Unknown parameter
- Yang, Xiaobo; Yu, Yuan; Xu, Jiqian; et al. (24 កុម្ភៈ 2020) "Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study" Lancet 8 (5): 475–481 doi:10.1016/S2213-2600(20)30079-5 PMC 7102538 Check
|pmc=value (ជំនួយ) PMID 32105632 Check
... 52 critically ill adult patients ... fever (98%) ... [of which] fever was not detected at the onset of illness in six (11·5%) ...
- Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. (កុម្ភៈ 2020) "Clinical Characteristics of Coronavirus Disease 2019 in China" The New England Journal of Medicine Massachusetts Medical Society 382 (18): 1708–1720 doi:10.1056/nejmoa2002032 PMC 7092819 Check
|pmc=value (ជំនួយ) PMID 32109013 Check
- Hessen MT (27 មករា 2020) "Novel Coronavirus Information Center: Expert guidance and commentary" Elsevier Connect បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ30 មករា 2020 ដកស្រង់នៅថ្ងៃ 31 មករា 2020 Unknown parameter
- Wei, Xiao-Shan; Wang, Xuan; Niu, Yi-Ran; Ye, Lin-Lin; Peng, Wen-Bei; Wang, Zi-Hao; Yang, Wei-Bing; Yang, Bo-Han; Zhang, Jian-Chu; Ma, Wan-Li; Wang, Xiao-Rong; Zhou, Qiong (26 កុម្ភៈ 2020) "Clinical Characteristics of SARS-CoV-2 Infected Pneumonia with Diarrhea" doi:10.2139/ssrn.3546120
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. (កុម្ភៈ 2020) "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China" Lancet 395 (10223): 497–506 doi:10.1016/S0140-6736(20)30183-5 PMC 7159299 Check
|pmc=value (ជំនួយ) PMID 31986264
- Lai, Chih-Cheng; Shih, Tzu-Ping; Ko, Wen-Chien; Tang, Hung-Jen; Hsueh, Po-Ren (1 មីនា 2020) "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges" International Journal of Antimicrobial Agents 55 (3): 105924 doi:10.1016/j.ijantimicag.2020.105924 ISSN 0924-8579 PMC 7127800 Check
|pmc=value (ជំនួយ) PMID 32081636 Check
- Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) (Report). World Health Organization (WHO). 16–24 February 2020. https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf។ បានយកមក 21 March 2020.
- Zheng YY, Ma YT, Zhang JY, Xie X (មីនា 2020) "COVID-19 and the cardiovascular system" Nature Reviews. Cardiology 17 (5): 259–260 doi:10.1038/s41569-020-0360-5 PMC 7095524 Check
|pmc=value (ជំនួយ) PMID 32139904 Check
- Xydakis MS, Dehgani-Mobaraki P, Holbrook EH, Geisthoff UW, Bauer C, Hautefort C, et al. (15 មេសា 2020) "Smell and taste dysfunction in patients with COVID-19" Lancet Infectious Diseases doi:10.1016/S1473-3099(20)30293-0 PMC 7159875 Check
|pmc=value (ជំនួយ) PMID 32304629 Check
|pmid=value (ជំនួយ) ដកស្រង់នៅថ្ងៃ 21 មេសា 2020
- "Symptoms of Coronavirus" Centers for Disease Control and Prevention 27 មេសា 2020 ដកស្រង់នៅថ្ងៃ 28 មេសា 2020 Unknown parameter
- Iacobucci, Gareth (2020) "Sixty seconds on ... anosmia" BMJ 368: m1202 doi:10.1136/bmj.m1202 ISSN 1756-1833 PMID 32209546 Check
- World Health Organization (19 កុម្ភៈ 2020) "Coronavirus disease 2019 (COVID-19): situation report, 29" World Health Organization (WHO) hdl:10665/331118
- "Q&A on coronaviruses (COVID-19): How long is the incubation period for COVID-19?" World Health Organization (WHO) បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ20 មករា 2020 ដកស្រង់នៅថ្ងៃ 26 កុម្ភៈ 2020 Unknown parameter
- Lauer, Stephen A.; Grantz, Kyra H.; Bi, Qifang; Jones, Forrest K.; Zheng, Qulu; Meredith, Hannah R.; Azman, Andrew S.; Reich, Nicholas G.; Lessler, Justin (10 មីនា 2020) "The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application" Annals of Internal Medicine 172 (9): 577 doi:10.7326/M20-0504 ISSN 0003-4819 PMC 7081172 Check
|pmc=value (ជំនួយ) PMID 32150748 Check
- "Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand" (PDF) Imperial College COVID-19 Response Team 16 មីនា 2020 ដកស្រង់នៅថ្ងៃ 21 មេសា 2020
- Mizumoto, Kenji; Kagaya, Katsushi; Zarebski, Alexander; Chowell, Gerardo (2020) "Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020" (PDF) Euro Surveillance 25 (10) doi:10.2807/1560-7917.ES.2020.25.10.2000180 PMC 7078829 Check
|pmc=value (ជំនួយ) PMID 32183930 Check
|pmid=value (ជំនួយ) ដកស្រង់នៅថ្ងៃ 21 មេសា 2020
- "Clinical Questions about COVID-19: Questions and Answers" Centers for Disease Control and Prevention 11 កុម្ភៈ 2020 បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ14 កុម្ភៈ 2020 ដកស្រង់នៅថ្ងៃ 31 មីនា 2020 Unknown parameter
- Lai, Chich-Cheng; Liu, Yen Hung; Wang, Cheng-Yi; Wang, Ya-Hui; Hsueh, Shun-Chung; Yen, Muh-Yen; Ko, Wen-Chien; Hsueh, Po-Ren (4 មីនា 2020) "Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths" Journal of Microbiology, Immunology, and Infection doi:10.1016/j.jmii.2020.02.012 PMC 7128959 Check
|pmc=value (ជំនួយ) PMID 32173241 Check
- Bai, Yan; Yao, Lingsheng; Wei, Tao; Tian, Fei; Jin, Dong-Yan; Chen, Lijuan; Wang, Meiyun (21 កុម្ភៈ 2020) "Presumed Asymptomatic Carrier Transmission of COVID-19" JAMA 323 (14): 1406 doi:10.1001/jama.2020.2565 ISSN 0098-7484 PMC 7042844 Check
|pmc=value (ជំនួយ) PMID 32083643 Check
- "China Reveals 1,541 Symptom-Free Virus Cases Under Pressure" www.bloomberg.com 31 មីនា 2020 ដកស្រង់នៅថ្ងៃ 31 មីនា 2020 Unknown parameter
- "코로나19 국내 발생현황 브리핑 (20. 03. 16. 14시)" ktv.go.kr (កូរ៉េ) ដកស្រង់នៅថ្ងៃ 31 មីនា 2020
- Carod-Artal, FJ (1 ឧសភា 2020) "Neurological complications of coronavirus and COVID-19." Revista de neurologia 70 (9): 311–322 doi:10.33588/rn.7009.2020179 PMID 32329044 Check
- Long, B; Brady, WJ; Koyfman, A; Gottlieb, M (18 មេសា 2020) "Cardiovascular complications in COVID-19." The American Journal of Emergency Medicine doi:10.1016/j.ajem.2020.04.048 PMC 7165109 Check
|pmc=value (ជំនួយ) PMID 32317203 Check
- Heymann DL, Shindo N, et al. (WHO Scientific and Technical Advisory Group for Infectious Hazards) (កុម្ភៈ 2020) "COVID-19: what is next for public health?" Lancet Elsevier BV 395 (10224): 542–545 doi:10.1016/s0140-6736(20)30374-3 PMC 7138015 Check
|pmc=value (ជំនួយ) PMID 32061313 Check
- Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R (2020) "Features, Evaluation and Treatment Coronavirus (COVID-19)" StatPearls Treasure Island (FL): StatPearls Publishing PMID 32150360 Check
|pmid=value (ជំនួយ) ដកស្រង់នៅថ្ងៃ 18 មីនា 2020
- Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. (2020) "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study" The Lancet Elsevier BV 395 (10229): 1054–1062 doi:10.1016/s0140-6736(20)30566-3 ISSN 0140-6736 PMID 32171076 Check
- Sanders, JM; Monogue, ML; Jodlowski, TZ; Cutrell, JB (13 មេសា 2020) "Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review" JAMA doi:10.1001/jama.2020.6019 PMID 32282022 Check
- Xu L, Liu J, Lu M, Yang D, Zheng X (មីនា 2020) "Liver injury during highly pathogenic human coronavirus infections" Liver International 40 (5): 998–1004 doi:10.1111/liv.14435 PMID 32170806 Check
- van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. (មីនា 2020) "Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1" New England Journal of Medicine 382 (16): 1564–7 doi:10.1056/NEJMc2004973 ISSN 0028-4793 PMC 7121658 Check
|pmc=value (ជំនួយ) PMID 32182409 Check
- CDC (24 មេសា 2020) "Household cleaners and disinfectants can cause health problems when not used properly. Follow the instructions on the product label to ensure safe and effective use. Learn more about cleaning and disinfecting your home: https://bit.ly/2S2a9yc .pic.twitter.com/rdcR9QJNIR" @cdcgov (អង់គ្លេស) ដកស្រង់នៅថ្ងៃ 6 ឧសភា 2020
- To, Kelvin Kai-Wang; Tsang, Owen Tak-Yin; Yip, Cyril Chik-Yan; Chan, Kwok-Hung; et al. (12 កុម្ភៈ 2020) "Consistent Detection of 2019 Novel Coronavirus in Saliva" Clinical Infectious Diseases Oxford University Press doi:10.1093/cid/ciaa149 PMC 7108139 Check
|pmc=value (ជំនួយ) PMID 32047895 Check
- "Coronavirus disease 2019 (COVID-19) Situation Report—73" (PDF) World Health Organization 2 មេសា 2020 ដកស្រង់នៅថ្ងៃ 3 មេសា 2020 Unknown parameter
- Coronavirus disease 2019 (COVID-19) in the EU/EEA and the UK – ninth update, 23 April 2020. Stockholm: ECDC, p.8-9.
- "COVID-19 and Our Communities -ACON – We are a New South Wales based health promotion organisation specialising in HIV prevention, HIV support and lesbian, gay, bisexual, transgender and intersex (LGBTI) health" Acon.org.au ដកស្រង់នៅថ្ងៃ 29 មេសា 2020
- "Sex and Coronavirus Disease 2019 (COVID-19)" (PDF) nyc.gov 27 មីនា 2020 ដកស្រង់នៅថ្ងៃ 29 មេសា 2020 Unknown parameter
- "Outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): increased transmission beyond China—fourth update" (PDF) European Centre for Disease Prevention and Control 14 កុម្ភៈ 2020 ដកស្រង់នៅថ្ងៃ 8 មីនា 2020
- Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF (17 មីនា 2020) "The proximal origin of SARS-CoV-2" Nature Medicine 26 (4): 450–452 doi:10.1038/s41591-020-0820-9 ISSN 1546-170X PMC 7095063 Check
|pmc=value (ជំនួយ) PMID 32284615 Check
- Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. (កុម្ភៈ 2020) "A Novel Coronavirus from Patients with Pneumonia in China, 2019" The New England Journal of Medicine 382 (8): 727–733 doi:10.1056/NEJMoa2001017 PMC 7092803 Check
|pmc=value (ជំនួយ) PMID 31978945
- Cyranoski D (26 កុម្ភៈ 2020) "Mystery deepens over animal source of coronavirus" Nature 579 (7797): 18–19 Bibcode:2020Natur.579...18C doi:10.1038/d41586-020-00548-w PMID 32127703 Check
- Letko M, Marzi A, Munster V (2020) "Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses" Nature Microbiology 5 (4): 562–569 doi:10.1038/s41564-020-0688-y PMC 7095430 Check
|pmc=value (ជំនួយ) PMID 32094589 Check
- Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS (មីនា 2020) "Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target" Intensive Care Medicine 46 (4): 586–590 doi:10.1007/s00134-020-05985-9 PMC 7079879 Check
|pmc=value (ជំនួយ) PMID 32125455 Check
- Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, et al. (កុម្ភៈ 2020) "High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa" International Journal of Oral Science 12 (1): 8 doi:10.1038/s41368-020-0074-x PMC 7039956 Check
|pmc=value (ជំនួយ) PMID 32094336 Check
- Gurwitz D (មីនា 2020) "Angiotensin receptor blockers as tentative SARS‐CoV‐2 therapeutics" Drug Development Research doi:10.1002/ddr.21656 PMID 32129518 Check
- Li, Yan-Chao; Bai, Wan-Zhu; Hashikawa, Tsutomu (2020) "The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients" Journal of Medical Virology (អង់គ្លេស) 92 (6): 552–555 doi:10.1002/jmv.25728 ISSN 1096-9071 PMID 32104915 Check
- Baig, Abdul Mannan; Khaleeq, Areeba; Ali, Usman; Syeda, Hira (មីនា 2020) "Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host–Virus Interaction, and Proposed Neurotropic Mechanisms" ACS Chemical Neuroscience 11 (7): 995–998 doi:10.1021/acschemneuro.0c00122 ISSN 1948-7193 PMC 7094171 Check
|pmc=value (ជំនួយ) PMID 32167747 Check
- Gu, Jinyang; Han, Bing; Wang, Jian (27 កុម្ភៈ 2020) "COVID-19: Gastrointestinal manifestations and potential fecal-oral transmission" Gastroenterology 158 (6): 1518–1519 doi:10.1053/j.gastro.2020.02.054 ISSN 0016-5085 PMC 7130192 Check
|pmc=value (ជំនួយ) PMID 32142785 Check
- Hamming, I.; Timens, W.; Bulthuis, M. L. C.; Lely, A. T.; Navis, G. J.; Goor, H. van (2004) "Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis" The Journal of Pathology 203 (2): 631–637 doi:10.1002/path.1570 ISSN 1096-9896 PMC 7167720 Check
|pmc=value (ជំនួយ) PMID 15141377
- Zheng, Ying-Ying; Ma, Yi-Tong; Zhang, Jin-Ying; Xie, Xiang (មីនា 2020) "COVID-19 and the cardiovascular system" Nature Reviews Cardiology 17 (5): 259–260 doi:10.1038/s41569-020-0360-5 ISSN 1759-5010 PMC 7095524 Check
|pmc=value (ជំនួយ) PMID 32139904 Check
- Wang, Dawei; Hu, Bo; Hu, Chang; Zhu, Fangfang; Liu, Xing; Zhang, Jing; Wang, Binbin; Xiang, Hui; Cheng, Zhenshun; Xiong, Yong; Zhao, Yan (មីនា 2020) "Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China" JAMA 323 (11): 1061–1069 doi:10.1001/jama.2020.1585 ISSN 0098-7484 PMC 7042881 Check
|pmc=value (ជំនួយ) PMID 32031570 Check
- Turner, Anthony J.; Hiscox, Julian A.; Hooper, Nigel M. (1 មិថុនា 2004) "ACE2: from vasopeptidase to SARS virus receptor" Trends in Pharmacological Sciences 25 (6): 291–294 doi:10.1016/j.tips.2004.04.001 ISSN 0165-6147 PMC 7119032 Check
|pmc=value (ជំនួយ) PMID 15165741
- Klok, F.A.; Kruip, M.J.H.A.; van der Meer, N.J.M.; Arbous, M.S.; Gommers, D.A.M.P.J.; Kant, K.M.; Kaptein, F.H.J.; van Paassen, J.; Stals, M.A.M.; Huisman, M.V.; Endeman, H. (មេសា 2020) "Incidence of thrombotic complications in critically ill ICU patients with COVID-19" Thrombosis Research doi:10.1016/j.thromres.2020.04.013 ISSN 0049-3848 PMC 7146714 Check
|pmc=value (ជំនួយ) PMID 32291094 Check
- Cui, Songping; Chen, Shuo; Li, Xiunan; Liu, Shi; Wang, Feng (9 មេសា 2020) "Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia" Journal of Thrombosis and Haemostasis doi:10.1111/jth.14830 PMID 32271988 Check
- Wadman, Meredith (មេសា 2020) "How does coronavirus kill? Clinicians trace a ferocious rampage through the body, from brain to toes" Science doi:10.1126/science.abc3208
- Diao, Bo; Wang, Chenhui; Wang, Rongshuai; Feng, Zeqing; Tan, Yingjun; Wang, Huiming; Wang, Changsong; Liu, Liang; Liu, Ying; Liu, Yueping; Wang, Gang; Yuan, Zilin; Ren, Liang; Wu, Yuzhang; Chen, Yongwen (10 មេសា 2020) "Human Kidney is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection" MedRxiv: 2020.03.04.20031120 doi:10.1101/2020.03.04.20031120 – តាមរយៈ www.medrxiv.org
- Barton L, Duval E, Stroberg E, Ghosh S, Mukhopadhyay S (មេសា 2020) "COVID-19 autopsies, Oklahoma, USA" American Journal of Clinical Pathology 153 (6): 725–733 doi:10.1093/ajcp/aqaa062 PMC 7184436 Check
|pmc=value (ជំនួយ) PMID 32275742 Check
- Zhang C, Wu Z, Li JW, Zhao H, Wang GQ (មីនា 2020) "The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality" International Journal of Antimicrobial Agents: 105954 doi:10.1016/j.ijantimicag.2020.105954 PMC 7118634 Check
|pmc=value (ជំនួយ) PMID 32234467 Check
- Zhou Y, Fu B, Zheng X, Wang D, Zhao C, Qi Y, et al. (2020) "Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus" bioRxiv Pre-print: 2020.02.12.945576 doi:10.1101/2020.02.12.945576
- "CDC Tests for 2019-nCoV" Centers for Disease Control and Prevention 5 កុម្ភៈ 2020 បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ14 កុម្ភៈ 2020 ដកស្រង់នៅថ្ងៃ 12 កុម្ភៈ 2020 Unknown parameter
- "Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases" World Health Organization (WHO) បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ17 មីនា 2020 ដកស្រង់នៅថ្ងៃ 13 មីនា 2020 Unknown parameter
- "2019 Novel Coronavirus (2019-nCoV) Situation Summary" Centers for Disease Control and Prevention 30 មករា 2020 បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ26 មករា 2020 ដកស្រង់នៅថ្ងៃ 30 មករា 2020 Unknown parameter
- "Real-Time RT-PCR Panel for Detection 2019-nCoV" Centers for Disease Control and Prevention 29 មករា 2020 បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ30 មករា 2020 ដកស្រង់នៅថ្ងៃ 1 កុម្ភៈ 2020 Unknown parameter
- "Curetis Group Company Ares Genetics and BGI Group Collaborate to Offer Next-Generation Sequencing and PCR-based Coronavirus (2019-nCoV) Testing in Europe" GlobeNewswire News Room 30 មករា 2020 បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ31 មករា 2020 ដកស្រង់នៅថ្ងៃ 1 កុម្ភៈ 2020 Unknown parameter
- Brueck H (30 មករា 2020) "There's only one way to know if you have the coronavirus, and it involves machines full of spit and mucus" Business Insider បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ1 កុម្ភៈ 2020 ដកស្រង់នៅថ្ងៃ 1 កុម្ភៈ 2020 Unknown parameter
- "Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases" បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ21 កុម្ភៈ 2020 ដកស្រង់នៅថ្ងៃ 26 កុម្ភៈ 2020 Unknown parameter
- Cohen J, Normile D (មករា 2020) "New SARS-like virus in China triggers alarm" (PDF) Science 367 (6475): 234–35 Bibcode:2020Sci...367..234C doi:10.1126/science.367.6475.234 PMID 31949058 បណ្ណសារចម្លងពីខ្លឹមសារដើម (PDF)នៅ11 កុម្ភៈ 2020 ដកស្រង់នៅថ្ងៃ 11 កុម្ភៈ 2020 Unknown parameter
- "Severe acute respiratory syndrome coronavirus 2 data hub" NCBI បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ21 មីនា 2020 ដកស្រង់នៅថ្ងៃ 4 មីនា 2020 Unknown parameter
- Petherick, Anna (4 មេសា 2020) "Developing antibody tests for SARS-CoV-2" The Lancet 395 (10230): 1101–1102 doi:10.1016/s0140-6736(20)30788-1 ISSN 0140-6736 PMID 32247384 Check
- Vogel, Gretchen (មីនា 2020) "New blood tests for antibodies could show true scale of coronavirus pandemic" Science doi:10.1126/science.abb8028
- Pang J, Wang MX, Ang IY, Tan SH, Lewis RF, Chen JI, et al. (កុម្ភៈ 2020) "Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review" Journal of Clinical Medicine 9 (3): 623 doi:10.3390/jcm9030623 PMC 7141113 Check
|pmc=value (ជំនួយ) PMID 32110875 Check
- AFP News Agency (11 April 2020). "How false negatives are complicating COVID-19 testing". Al Jazeera website Retrieved 12 April 2020.
- FDA (21 March 2020)។ "Coronavirus (COVID-19) Update: FDA Issues first Emergency Use Authorization for Point of Care Diagnostic"។ Press release។ https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-first-emergency-use-authorization-point-care-diagnostic។ បានយកមក 22 March 2020។
- Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, et al. (កុម្ភៈ 2020) "A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)" Military Medical Research 7 (1): 4 doi:10.1186/s40779-020-0233-6 PMC 7003341 Check
|pmc=value (ជំនួយ) PMID 32029004 Check
- Lee, Elaine Y. P.; Ng, Ming-Yen; Khong, Pek-Lan (24 កុម្ភៈ 2020) "COVID-19 pneumonia: what has CT taught us?" The Lancet Infectious Diseases 0 (4): 384–385 doi:10.1016/S1473-3099(20)30134-1 ISSN 1473-3099 PMC 7128449 Check
|pmc=value (ជំនួយ) PMID 32105641 Check
|pmid=value (ជំនួយ) បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ8 មីនា 2020 ដកស្រង់នៅថ្ងៃ 13 មីនា 2020 Unknown parameter
- "ICD-10 Version:2019" World Health Organization 2019 បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ31 មីនា 2020 ដកស្រង់នៅថ្ងៃ 31 មីនា 2020
U07.2—COVID-19, virus not identified—COVID-19 NOS—Use this code when COVID-19 is diagnosed clinically or epidemiologically but laboratory testing is inconclusive or not available. Use additional code, if desired, to identify pneumonia or other manifestationsUnknown parameter
- Hanley B, Lucas SB, Youd E, Swift B, Osborn M (មីនា 2020) "Autopsy in suspected COVID-19 cases" J. Clin. Pathol. 73 (5): jclinpath-2020–206522 doi:10.1136/jclinpath-2020-206522 PMID 32198191 Check
- Yao XH, Li TY, He ZC, Ping YF, Liu HW, Yu SC, et al. (មីនា 2020) "[A pathological report of three COVID-19 cases by minimally invasive autopsies]" Zhonghua Bing Li Xue Za Zhi (Chinese) 49: E009 doi:10.3760/cma.j.cn112151-20200312-00193 PMID 32172546 Check
|pmid=value (ជំនួយ)CS1 maint: Unrecognized language (link)
- Giani, Marco; Seminati, Davide; Lucchini, Alberto; Foti, Giuseppe; Pagni, Fabio (16 មីនា 2020) "Exuberant plasmocytosis in bronchoalveolar lavage of the first patient requiring Extracorporeal Membrane Oxygenation for SARS-CoV-2 in Europe" Journal of Thoracic Oncology 15 (5): e65–e66 doi:10.1016/j.jtho.2020.03.008 PMC 7118681 Check
|pmc=value (ជំនួយ) PMID 32194247 Check
- Lillicrap, David (1 មេសា 2020) "Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia" Journal of Thrombosis and Haemostasis: JTH 18 (4): 786–787 doi:10.1111/jth.14781 PMC 7166410 Check
|pmc=value (ជំនួយ) PMID 32212240 Check
- Mitra, Anupam; Dwyre, Denis M.; Schivo, Michael; Thompson, George R.; Cohen, Stuart H.; Ku, Nam; Graff, John P. (25 មីនា 2020) "Leukoerythroblastic reaction in a patient with COVID-19 infection" American Journal of Hematology doi:10.1002/ajh.25793 PMID 32212392 Check
- Wiles S (9 មីនា 2020) "The three phases of Covid-19—and how we can make it manageable" The Spinoff បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ27 មីនា 2020 ដកស្រង់នៅថ្ងៃ 9 មីនា 2020 Unknown parameter
- Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD (មីនា 2020) "How will country-based mitigation measures influence the course of the COVID-19 epidemic?" Lancet 395 (10228): 931–934 doi:10.1016/S0140-6736(20)30567-5 PMC 7158572 Check
|pmc=value (ជំនួយ) PMID 32164834 Check
A key issue for epidemiologists is helping policy makers decide the main objectives of mitigation—e.g. minimising morbidity and associated mortality, avoiding an epidemic peak that overwhelms health-care services, keeping the effects on the economy within manageable levels, and flattening the epidemic curve to wait for vaccine development and manufacture on scale and antiviral drug therapies.
- Barclay E (10 មីនា 2020) "How canceled events and self-quarantines save lives, in one chart" Vox បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ12 មីនា 2020 ដកស្រង់នៅថ្ងៃ 12 មីនា 2020 Unknown parameter
- Barclay, Eliza; Scott, Dylan; Animashaun, Animashaun (7 មេសា 2020) "The US doesn't just need to flatten the curve. It needs to "raise the line."" Vox បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ7 មេសា 2020 Unknown parameter
- Wiles, Siouxsie (14 មីនា 2020) "After 'Flatten the Curve', we must now 'Stop the Spread'. Here's what that means" The Spinoff បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ26 មីនា 2020 ដកស្រង់នៅថ្ងៃ 13 មីនា 2020 Unknown parameter
- Centers for Disease Control (3 កុម្ភៈ 2020) "Coronavirus Disease 2019 (COVID-19): Prevention & Treatment" បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ15 ធ្នូ 2019 ដកស្រង់នៅថ្ងៃ 10 កុម្ភៈ 2020 Unknown parameter
- World Health Organization "Advice for Public" បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ26 មករា 2020 ដកស្រង់នៅថ្ងៃ 10 កុម្ភៈ 2020 Unknown parameter
- "My Hand-Washing Song: Readers Offer Lyrics For A 20-Second Scrub" NPR.org បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ20 មីនា 2020 ដកស្រង់នៅថ្ងៃ 20 មីនា 2020 Unknown parameter
- CDC (11 កុម្ភៈ 2020) "Recommendation Regarding the Use of Cloth Face Coverings, Especially in Areas of Significant Community-Based Transmission" Centers for Disease Control and Prevention ដកស្រង់នៅថ្ងៃ 17 មេសា 2020 Unknown parameter
- "COVID-19 Treatment Guidelines" www.nih.gov National Institutes of Health ដកស្រង់នៅថ្ងៃ 21 មេសា 2020
- Maragakis LL "Coronavirus, Social Distancing and Self Quarantine" www.hopkinsmedicine.org Johns Hopkins University បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ18 មីនា 2020 ដកស្រង់នៅថ្ងៃ 18 មីនា 2020 Unknown parameter
- Parker-Pope T (19 មីនា 2020) "Deciding How Much Distance You Should Keep" The New York Times ISSN 0362-4331 បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ20 មីនា 2020 ដកស្រង់នៅថ្ងៃ 20 មីនា 2020 Unknown parameter
- Sanders, JM; Monogue, ML; Jodlowski, TZ; Cutrell, JB (13 មេសា 2020) "Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review" JAMA doi:10.1001/jama.2020.6019 PMID 32282022 Check
- Systrom K, Krieger M, O'Rourke R, Stein R, Dellaert F, Lerer A (11 មេសា 2020) "Rt Covid-19" rt.live ដកស្រង់នៅថ្ងៃ 19 មេសា 2020 Based on Bettencourt, Luís M. A.; Ribeiro, Ruy M. (14 ឧសភា 2008) "Real Time Bayesian Estimation of the Epidemic Potential of Emerging Infectious Diseases" PLOS ONE 3 (5): e2185 Bibcode:2008PLoSO...3.2185B doi:10.1371/journal.pone.0002185 ISSN 1932-6203 PMC 2366072 PMID 18478118
- Grenfell R, Drew T (17 កុម្ភៈ 2020) "Here's Why It's Taking So Long to Develop a Vaccine for the New Coronavirus" Science Alert បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ28 កុម្ភៈ 2020 ដកស្រង់នៅថ្ងៃ 26 កុម្ភៈ 2020 Unknown parameter
- "When and how to use masks" World Health Organization (WHO) បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ7 មីនា 2020 ដកស្រង់នៅថ្ងៃ 8 មីនា 2020 Unknown parameter
- Staff (8 មេសា 2020) "Using face masks in the community—Technical Report" (PDF) ECDC Unknown parameter
- "For different groups of people: how to choose masks" NHC.gov.cn National Health Commission of the People's Republic of China 7 កុម្ភៈ 2020 ដកស្រង់នៅថ្ងៃ 22 មីនា 2020
Disposable medical masks: Recommended for: · People in crowded places · Indoor working environment with a relatively dense population · People going to medical institutions · Children in kindergarten and students at school gathering to study and do other activities[តំណភ្ជាប់ខូច]
- "Prevention of Coronavirus Disease 2019 (COVID-19)" (PDF) Centre for Health Protection បណ្ណសារចម្លងពីខ្លឹមសារដើម (PDF)នៅ21 មីនា 2020 ដកស្រង់នៅថ្ងៃ 22 មីនា 2020
Wear a surgical mask when taking public transport or staying in crowded places.Unknown parameter
- Staff (11 មេសា 2020) "Spain officially recommends face mask use" Gazette Life ដកស្រង់នៅថ្ងៃ 20 មេសា 2020 Unknown parameter
- Giuffrida, Angela; Beaumont, Peter (5 មេសា 2020) "Lombardy insists on face masks outside homes to stop Covid-19" The Guardian ISSN 0261-3077 ដកស្រង់នៅថ្ងៃ 20 មេសា 2020 Unknown parameter
- "Russian sanitary watchdog chief supports regions binding people to wear face masks" Tass 1 ឧសភា 2020 ដកស្រង់នៅថ្ងៃ 3 ឧសភា 2020 Unknown parameter
- "Coronavirus Disease 2019 (COVID-19)—Prevention & Treatment" Centers for Disease Control and Prevention U.S. Department of Health & Human Services 10 មីនា 2020 បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ11 មីនា 2020 ដកស្រង់នៅថ្ងៃ 11 មីនា 2020 Unknown parameter
- "WHO-recommended handrub formulations" WHO Guidelines on Hand Hygiene in Health Care: First Global Patient Safety Challenge Clean Care Is Safer Care. World Health Organization 19 មីនា 2009 ដកស្រង់នៅថ្ងៃ 19 មីនា 2020
- Fisher D, Heymann D (កុម្ភៈ 2020) "Q&A: The novel coronavirus outbreak causing COVID-19" BMC Medicine 18 (1): 57 doi:10.1186/s12916-020-01533-w PMC 7047369 Check
|pmc=value (ជំនួយ) PMID 32106852 Check
- Kui L, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, et al. (កុម្ភៈ 2020) "Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province" Chinese Medical Journal 133 (9): 1025–1031 doi:10.1097/CM9.0000000000000744 PMC 7147277 Check
|pmc=value (ជំនួយ) PMID 32044814 Check
- Wang T, Du Z, Zhu F, Cao Z, An Y, Gao Y, Jiang B (មីនា 2020) "Comorbidities and multi-organ injuries in the treatment of COVID-19" Lancet Elsevier BV 395 (10228): e52 doi:10.1016/s0140-6736(20)30558-4 PMID 32171074 Check
- Henry BM (2020) "COVID-19, ECMO, and lymphopenia: a word of caution" The Lancet Respiratory Medicine Elsevier BV 8 (4): e24 doi:10.1016/s2213-2600(20)30119-3 ISSN 2213-2600 PMC 7118650 Check
|pmc=value (ជំនួយ) PMID 32178774 Check
- Wang, Li-sheng; Wang, Yi-ru; Ye, Da-wei; Liu, Qing-quan (19 មីនា 2020) "A review of the 2019 novel coronavirus (COVID-19) based on current evidence" International Journal of Antimicrobial Agents: 105948 doi:10.1016/j.ijantimicag.2020.105948 ISSN 0924-8579 PMC 7156162 Check
|pmc=value (ជំនួយ) PMID 32201353 Check
|pmid=value (ជំនួយ) បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ27 មីនា 2020 ដកស្រង់នៅថ្ងៃ 27 មីនា 2020 Unknown parameter
- Wang, Yixuan; Wang, Yuyi; Chen, Yan; Qin, Qingsong (2020) "Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures" Journal of Medical Virology n/a (n/a): 568–576 doi:10.1002/jmv.25748 ISSN 1096-9071 PMID 32134116 Check
- Cheng ZJ, Shan J (កុម្ភៈ 2020) "2019 Novel coronavirus: where we are and what we know" Infection 48 (2): 155–163 doi:10.1007/s15010-020-01401-y PMC 7095345 Check
|pmc=value (ជំនួយ) PMID 32072569 Check
- "Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected" World Health Organization (WHO) បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ31 មករា 2020 ដកស្រង់នៅថ្ងៃ 13 កុម្ភៈ 2020 Unknown parameter
- Farkas J (មីនា 2020) COVID-19—The Internet Book of Critical Care (Reference manual) USA: EMCrit បណ្ណសារចម្លងពីខ្លឹមសារដើម (digital)នៅ11 មីនា 2020 ដកស្រង់នៅថ្ងៃ 13 មីនា 2020 Unknown parameter
- "COVID19—Resources for Health Care Professionals" Penn Libraries 11 មីនា 2020 បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ14 មីនា 2020 ដកស្រង់នៅថ្ងៃ 13 មីនា 2020 Unknown parameter
- "Frequently Asked Questions on the Emergency Use Authorization for Remdesivir for Certain Hospitalized COVID‐19 Patients" (PDF) U.S. Food and Drug Administration (FDA) 1 ឧសភា 2020 ដកស្រង់នៅថ្ងៃ 1 ឧសភា 2020 ទំព័រគំរូ:PD-notice
- Day, Michael (17 មីនា 2020) "Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists" BMJ 368: m1086 doi:10.1136/bmj.m1086 ISSN 1756-1833 PMID 32184201 Check
|pmid=value (ជំនួយ) បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ19 មីនា 2020 ដកស្រង់នៅថ្ងៃ 18 មីនា 2020 Unknown parameter
- "Self-isolation advice—Coronavirus (COVID-19)" National Health Service (United Kingdom) 28 កុម្ភៈ 2020 បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ28 មីនា 2020 ដកស្រង់នៅថ្ងៃ 27 មីនា 2020 Unknown parameter
- Godoy, Maria (18 មីនា 2020) "Concerned About Taking Ibuprofen For Coronavirus Symptoms? Here's What Experts Say" NPR ដកស្រង់នៅថ្ងៃ 8 មេសា 2020
- AFP (19 មីនា 2020) "Updated: WHO Now Doesn't Recommend Avoiding Ibuprofen For COVID-19 Symptoms" ScienceAlert បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ18 មីនា 2020 ដកស្រង់នៅថ្ងៃ 19 មីនា 2020 Unknown parameter
- Research, Center for Drug Evaluation and (19 មីនា 2020) "FDA advises patients on use of non-steroidal anti-inflammatory drugs (NSAIDs) for COVID-19" Drug Safety and Availability បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ27 មីនា 2020 ដកស្រង់នៅថ្ងៃ 27 មីនា 2020 Unknown parameter
- "Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician" បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ21 មីនា 2020 ដកស្រង់នៅថ្ងៃ 21 មីនា 2020 Unknown parameter
- "Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician"។ Press release។ 17 March 2020។ https://newsroom.heart.org/news/patients-taking-ace-i-and-arbs-who-contract-covid-19-should-continue-treatment-unless-otherwise-advised-by-their-physician។ បានយកមក 25 March 2020។
- de Simone, Giovanni "Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers" Council on Hypertension of the European Society of Cardiology បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ24 មីនា 2020 ដកស្រង់នៅថ្ងៃ 24 មីនា 2020 Unknown parameter
- "New Evidence Concerning Safety of ACE Inhibitors, ARBs in COVID-19" Pharmacy Times ដកស្រង់នៅថ្ងៃ 2 ឧសភា 2020
- Vetter P, Eckerle I, Kaiser L (កុម្ភៈ 2020) "Covid-19: a puzzle with many missing pieces" BMJ 368: m627 doi:10.1136/bmj.m627 PMID 32075791 Check
- "Novel Coronavirus—COVID-19: What Emergency Clinicians Need to Know" www.ebmedicine.net បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ14 មីនា 2020 ដកស្រង់នៅថ្ងៃ 9 មីនា 2020 Unknown parameter
- Grainger, Suzanne "ASCIA Position Statement: Specific Treatments for COVID-19" Australasian Society of Clinical Immunology and Allergy (ASCIA) (អង់គ្លេស) ដកស្រង់នៅថ្ងៃ 2 ឧសភា 2020
- Tang, Ning; Bai, Huan; Chen, Xing; Gong, Jiale; Li, Dengju; Sun, Ziyong (2020) "Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy" Journal of Thrombosis and Haemostasis n/a (n/a): 1094–1099 doi:10.1111/jth.14817 ISSN 1538-7836 PMID 32220112 Check
- "Sequence for Putting On Personal Protective Equipment (PPE)" (PDF) CDC បណ្ណសារចម្លងពីខ្លឹមសារដើម (PDF)នៅ5 មីនា 2020 ដកស្រង់នៅថ្ងៃ 8 មីនា 2020 Unknown parameter
- Cheung JC, Ho LT, Cheng JV, Cham EY, Lam KN (កុម្ភៈ 2020) "Staff safety during emergency airway management for COVID-19 in Hong Kong" Lancet Respiratory Medicine 8 (4): e19 doi:10.1016/s2213-2600(20)30084-9 PMC 7128208 Check
|pmc=value (ជំនួយ) PMID 32105633 Check
- "What healthcare personnel should know about caring for patients with confirmed or possible coronavirus disease 2" (PDF) CDC 12 មីនា 2020 ដកស្រង់នៅថ្ងៃ 31 មីនា 2020 Unknown parameter
- "Coronavirus Disease 2019 (COVID-19)" Centers for Disease Control and Prevention 11 កុម្ភៈ 2020 បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ4 មីនា 2020 ដកស្រង់នៅថ្ងៃ 11 មីនា 2020 Unknown parameter
- "Coronavirus Disease 2019 (COVID-19)" Centers for Disease Control and Prevention 11 កុម្ភៈ 2020 បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ4 មីនា 2020 ដកស្រង់នៅថ្ងៃ 8 មីនា 2020 Unknown parameter
- CDC (11 កុម្ភៈ 2020) "Interim Infection Prevention and Control Recommendations for Patients with Suspected or Confirmed Coronavirus Disease 2019 (COVID-19) in Healthcare Settings" Centers for Disease Control and Prevention បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ4 មីនា 2020 ដកស្រង់នៅថ្ងៃ 25 មីនា 2020 Unknown parameter
- "Coronavirus Disease 2019 (COVID-19) Frequently Asked Questions" Food and Drug Administration
- "Strategies for Optimizing the Supply of Facemasks" CDC 11 កុម្ភៈ 2020 បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ23 មីនា 2020 ដកស្រង់នៅថ្ងៃ 23 មីនា 2020 Unknown parameter
- Murthy S, Gomersall CD, Fowler RA (11 មីនា 2020) "Care for Critically Ill Patients With COVID-19" JAMA 323 (15): 1499 doi:10.1001/jama.2020.3633 PMID 32159735 Check
|pmid=value (ជំនួយ) បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ18 មីនា 2020 ដកស្រង់នៅថ្ងៃ 18 មីនា 2020 Unknown parameter
- World Health Organization (28 មករា 2020) "Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected" (PDF) បណ្ណសារចម្លងពីខ្លឹមសារដើម (PDF)នៅ26 កុម្ភៈ 2020 ដកស្រង់នៅថ្ងៃ 18 មីនា 2020 Unknown parameter
- Wang, Ke; Zhao, Wei; Li, Ji; Shu, Weiwei; Duan, Jun (30 មីនា 2020) "The experience of high-flow nasal cannula in hospitalized patients with 2019 novel coronavirus-infected pneumonia in two hospitals of Chongqing, China" Annals of Intensive Care 10 (1): 37 doi:10.1186/s13613-020-00653-z PMC 7104710 Check
|pmc=value (ជំនួយ) PMID 32232685 Check
- McEnery, Tom; Gough, Ciara; Costello, Richard W (មេសា 2020) "COVID-19: Respiratory support outside the intensive care unit" The Lancet Respiratory Medicine doi:10.1016/S2213-2600(20)30176-4 PMC 7146718 Check
|pmc=value (ជំនួយ) PMID 32278367 Check
- Ferguson, N.; Laydon, D.; Nedjati Gilani, G.; Imai, N.; Ainslie, K.; Baguelin, M.; Bhatia, S.; Boonyasiri, A.; Cucunuba Perez, Zulma; Cuomo-Dannenburg, G.; Dighe, A. (16 មីនា 2020) "Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand" Imperial College London Table 1 doi:10.25561/77482 hdl:20.1000/100 បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ21 មីនា 2020 ដកស្រង់នៅថ្ងៃ 25 មីនា 2020 Unknown parameter
- Scott, Dylan (16 មីនា 2020) "Coronavirus is exposing all of the weaknesses in the US health system High health care costs and low medical capacity made the US uniquely vulnerable to the coronavirus." Vox បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ18 មីនា 2020 ដកស្រង់នៅថ្ងៃ 18 មីនា 2020 Unknown parameter
- Matthay, Michael A.; Aldrich, J. Matthew; Gotts, Jeffrey E. (មីនា 2020) "Treatment for severe acute respiratory distress syndrome from COVID-19" The Lancet Respiratory Medicine 8 (5): 433–434 doi:10.1016/S2213-2600(20)30127-2 PMC 7118607 Check
|pmc=value (ជំនួយ) PMID 32203709 Check
- Briel, Matthias; Meade, Maureen; Mercat, Alain; Brower, Roy G.; Talmor, Daniel; Walter, Stephen D.; Slutsky, Arthur S.; Pullenayegum, Eleanor; Zhou, Qi; Cook, Deborah; Brochard, Laurent; Richard, Jean-Christophe M.; Lamontagne, François; Bhatnagar, Neera; Stewart, Thomas E.; Guyatt, Gordon (3 មីនា 2010) "Higher vs Lower Positive End-Expiratory Pressure in Patients With Acute Lung Injury and Acute Respiratory Distress Syndrome" JAMA 303 (9): 865–73 doi:10.1001/jama.2010.218 PMID 20197533
- Diaz, Raiko; Heller, Daniel (2020) Barotrauma And Mechanical Ventilation StatPearls StatPearls Publishing PMID 31424810
- "Chinese doctors using plasma therapy on coronavirus, WHO says 'very valid' approach" Reuters 17 កុម្ភៈ 2020 បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ4 មីនា 2020 ដកស្រង់នៅថ្ងៃ 19 មីនា 2020 Unknown parameter
- Steenhuysen J, Kelland K (24 មករា 2020) "With Wuhan virus genetic code in hand, scientists begin work on a vaccine" Reuters បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ25 មករា 2020 ដកស្រង់នៅថ្ងៃ 25 មករា 2020 Unknown parameter
- Duddu P (19 កុម្ភៈ 2020) "Coronavirus outbreak: Vaccines/drugs in the pipeline for Covid-19" clinicaltrialsarena.com បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ19 កុម្ភៈ 2020
- Lu H (28 មករា 2020) "Drug treatment options for the 2019-new coronavirus (2019-nCoV)." Biosci Trends 14 (1): 69–71 doi:10.5582/bst.2020.01020 PMID 31996494
- Li G, De Clercq E (មីនា 2020) "Therapeutic options for the 2019 novel coronavirus (2019-nCoV)" Nature Reviews. Drug Discovery 19 (3): 149–150 doi:10.1038/d41573-020-00016-0 PMID 32127666 Check
- Nebehay S, Kelland K, Liu R (5 កុម្ភៈ 2020) "WHO: 'no known effective' treatments for new coronavirus" Thomson Reuters បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ5 កុម្ភៈ 2020 ដកស្រង់នៅថ្ងៃ 5 កុម្ភៈ 2020 Unknown parameter
- "Blood plasma taken from covid-19 survivors might help patients fight off the disease" MIT Technology Review
- "Trials of Plasma From Recovered Covid-19 Patients Have Begun" Wired
- "FDA now allows treatment of life-threatening COVID-19 cases using blood from patients who have recovered" TechCrunch ដកស្រង់នៅថ្ងៃ 9 មេសា 2020
- "China launches coronavirus 'close contact' app" BBC News 11 កុម្ភៈ 2020 បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ28 កុម្ភៈ 2020 ដកស្រង់នៅថ្ងៃ 7 មីនា 2020 Unknown parameter
- Chen A "China's coronavirus app could have unintended consequences" MIT Technology Review ដកស្រង់នៅថ្ងៃ 7 មីនា 2020
- "Gov in the Time of Corona" GovInsider 19 មីនា 2020 បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ20 មីនា 2020 ដកស្រង់នៅថ្ងៃ 20 មីនា 2020 Unknown parameter
- Manancourt, Vincent (10 មីនា 2020) "Coronavirus tests Europe's resolve on privacy" POLITICO បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ20 មីនា 2020 ដកស្រង់នៅថ្ងៃ 20 មីនា 2020 Unknown parameter
- Tidy, Joe (17 មីនា 2020) "Coronavirus: Israel enables emergency spy powers" BBC News បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ18 មីនា 2020 ដកស្រង់នៅថ្ងៃ 18 មីនា 2020 Unknown parameter
- Bünte, Oliver (18 មីនា 2020) "Corona-Krise: Deutsche Telekom liefert anonymisierte Handydaten an RKI" [Corona crisis: Deutsche Telekom delivers anonymized cell phone data to RKI] Heise Online (German) បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ24 មីនា 2020 ដកស្រង់នៅថ្ងៃ 25 មីនា 2020 Unknown parameter
|url-status=ignored (ជំនួយ)CS1 maint: Unrecognized language (link)
- "Moscow deploys facial recognition technology for coronavirus quarantine" Reuters 21 កុម្ភៈ 2020 បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ22 កុម្ភៈ 2020 ដកស្រង់នៅថ្ងៃ 20 មីនា 2020 Unknown parameter
- "Italians scolded for flouting lockdown as death toll nears 3,000" Pittsburgh Post-Gazette បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ20 មីនា 2020 ដកស្រង់នៅថ្ងៃ 20 មីនា 2020 Unknown parameter
- "Kreative Lösungen gesucht" Startseite (អាល្លឺម៉ង់) បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ24 មីនា 2020 ដកស្រង់នៅថ្ងៃ 23 មីនា 2020 Unknown parameter
- Dannewitz, Juliane (23 មីនា 2020) "Hackathon Germany: #WirvsVirus" Datenschutzbeauftragter (អាល្លឺម៉ង់)
- Staff (8 មេសា 2020) "Lockdown is working, suggests latest data from symptom tracker app" Kings College London News Centre ដកស្រង់នៅថ្ងៃ 20 មេសា 2020 Unknown parameter
- Whyte, Andrew (21 មីនា 2020) "President makes global call to combat coronavirus via hackathon" ERR បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ24 មីនា 2020 ដកស្រង់នៅថ្ងៃ 23 មីនា 2020 Unknown parameter
- Xiang YT, Yang Y, Li W, Zhang L, Zhang Q, Cheung T, et al. (មីនា 2020) "Timely mental health care for the 2019 novel coronavirus outbreak is urgently needed" The Lancet. Psychiatry 7 (3): 228–29 doi:10.1016/S2215-0366(20)30046-8 PMC 7128153 Check
|pmc=value (ជំនួយ) PMID 32032543 Check
- Kang L, Li Y, Hu S, Chen M, Yang C, Yang BX, et al. (មីនា 2020) "The mental health of medical workers in Wuhan, China dealing with the 2019 novel coronavirus" The Lancet. Psychiatry 7 (3): e14 doi:10.1016/S2215-0366(20)30047-X PMC 7129673 Check
|pmc=value (ជំនួយ) PMID 32035030 Check
- Coronavirus: 'Profound' mental health impact prompts calls for urgent research, BBC, Philippa Roxby, April 16, 2020.
- Multidisciplinary research priorities for the COVID‑19 pandemic: a call for action for mental health science, The Lancet, Emily Holmes, Rory O'Connor, Hugh Perry, et al., April 15, 2020, page 1: "A fragmented research response, characterised by small-scale and localised initiatives, will not yield the clear insights necessary to guide policymakers or the public."
- Roser M, Ritchie H, Ortiz-Ospina E (4 មីនា 2020) "Coronavirus Disease (COVID-19)" Our World in Data បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ19 មីនា 2020 ដកស្រង់នៅថ្ងៃ 12 មីនា 2020 Unknown parameter
- Yanping Z, et al. (The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team) (17 កុម្ភៈ 2020) "The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19)—China, 2020" China CDC Weekly Chinese Center for Disease Control and Prevention 2 (8): 113–122 បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ19 កុម្ភៈ 2020 ដកស្រង់នៅថ្ងៃ 18 មីនា 2020 Unknown parameter
- (ជាko) 코로나바이러스감염증-19 국내 발생 현황(7월 17일, 정례브리핑) (Report). Korea Centers for Disease Control and Prevention. 2020-07-17. https://www.cdc.go.kr/board/board.es?mid=a20501000000&bid=0015&list_no=367829&act=view។ បានយកមក 2020-07-17.
- (ជាSpanish) Actualización nº 109. Enfermedad por el coronavirus (COVID-19) (Report). Ministerio de Sanidad, Consumo y Bienestar Social. 18 May 2020. https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/documentos/Actualizacion_109_COVID-19.pdf។ បានយកមក 20 May 2020. Cite error: Invalid
<ref>tag; name "MSCBSReport" defined multiple times with different content
- "Epidemia COVID-19 – Bollettino sorveglianza integrata COVID-19" (PDF) (អ៊ីតាលី) Istituto Superiore di Sanità 5 មិថុនា 2020 ដកស្រង់នៅថ្ងៃ 10 មិថុនា 2020
- Roser M, Ritchie H, Ortiz-Ospina E (6 មេសា 2020) "Coronavirus Disease (COVID-19)" Our World in Data ដកស្រង់នៅថ្ងៃ 6 មេសា 2020
- Castagnoli, R; Votto, M; Licari, A (មេសា 2020) "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents A Systematic Review" JAMA Pediatrics doi:10.1001/jamapediatrics.2020.1467 PMID 32320004 Check
|pmid=value (ជំនួយ) ដកស្រង់នៅថ្ងៃ 22 មេសា 2020
- Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. (18 មីនា 2020) "SARS-CoV-2 Infection in Children" New England Journal of Medicine Massachusetts Medical Society 382 (17): 1663–1665 doi:10.1056/nejmc2005073 ISSN 0028-4793 PMC 7121177 Check
|pmc=value (ជំនួយ) PMID 32187458 Check
- Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, Tong S (2020) "Epidemiological Characteristics of 2143 Pediatric Patients With 2019 Coronavirus Disease in China" (PDF) Pediatrics: e20200702 doi:10.1542/peds.2020-0702 PMID 32179660 Check
|pmid=value (ជំនួយ) បណ្ណសារចម្លងពីខ្លឹមសារដើម (PDF)នៅ17 មីនា 2020 ដកស្រង់នៅថ្ងៃ 16 មីនា 2020 Unknown parameter
- Fang L, Karakiulakis G, Roth M (មីនា 2020) "Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?" The Lancet Respiratory Medicine 395 (10224): e40 doi:10.1016/S0140-6736(20)30311-1 PMC 7118626 Check
|pmc=value (ជំនួយ) PMID 32171062 Check
- "Coronavirus Disease 2019 (COVID-19)" Centers for Disease Control and Prevention 11 កុម្ភៈ 2020 បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ2 មីនា 2020 ដកស្រង់នៅថ្ងៃ 2 មីនា 2020 Unknown parameter
- Tian, Dai-Shi; Wang, Wei; Shang, Ke; Ma, Ke; Xie, Cuihong; Tao, Yu; Yang, Sheng; Zhang, Shuoqi; Hu, Ziwei; Zhou, Luoqi; Qin, Chuan (12 មីនា 2020) "Dysregulation of immune response in patients with COVID-19 in Wuhan, China" Clinical Infectious Diseases doi:10.1093/cid/ciaa248 PMC 7108125 Check
|pmc=value (ជំនួយ) PMID 32161940 Check
- "WHO Director-General's statement on the advice of the IHR Emergency Committee on Novel Coronavirus" World Health Organization (WHO)
- Characteristics of COVID-19 patients dying in Italy Report based on available data on April 2th, 2020 (Report). Istituto Superiore di Sanità. 3 April 2020. https://www.epicentro.iss.it/en/coronavirus/bollettino/Report-COVID-2019_2_april_2020.pdf។ បានយកមក 3 April 2020.
- Wang W, Tang J, Wei F (មេសា 2020) "Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China" Journal of Medical Virology 92 (4): 441–47 doi:10.1002/jmv.25689 PMC 7167192 Check
|pmc=value (ជំនួយ) PMID 31994742
- "Coronavirus Age, Sex, Demographics (COVID-19)" www.worldometers.info បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ27 កុម្ភៈ 2020 ដកស្រង់នៅថ្ងៃ 26 កុម្ភៈ 2020 Unknown parameter
- Garg, Shikha; et al. (8 មេសា 2020) "Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019—COVID-NET, 14 States, March 1–30, 2020" MMWR. Morbidity and Mortality Weekly Report 69 (15): 458–464 doi:10.15585/mmwr.mm6915e3 ISSN 0149-2195 PMID 32298251 Check
- Ji Y, Ma Z, Peppelenbosch MP, Pan Q (កុម្ភៈ 2020) "Potential association between COVID-19 mortality and health-care resource availability" Lancet Global Health 8 (4): e480 doi:10.1016/S2214-109X(20)30068-1 PMC 7128131 Check
|pmc=value (ជំនួយ) PMID 32109372 Check
- Li XQ, Cai WF, Huang LF, Chen C, Liu YF, Zhang ZB, et al. (មីនា 2020) "[Comparison of epidemic characteristics between SARS in2003 and COVID-19 in 2020 in Guangzhou]" Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi (Chinese) 41 (5): 634–637 doi:10.3760/cma.j.cn112338-20200228-00209 PMID 32159317 Check
|pmid=value (ជំនួយ)CS1 maint: Unrecognized language (link)
- Jung SM, Akhmetzhanov AR, Hayashi K, Linton NM, Yang Y, Yuan B, et al. (កុម្ភៈ 2020) "Real-Time Estimation of the Risk of Death from Novel Coronavirus (COVID-19) Infection: Inference Using Exported Cases" Journal of Clinical Medicine 9 (2): 523 doi:10.3390/jcm9020523 PMC 7074479 Check
|pmc=value (ជំនួយ) PMID 32075152 Check
- Chughtai A, Malik A (មីនា 2020) "Is Coronavirus disease (COVID-19) case fatality ratio underestimated?" Global Biosecurity 1 (3) doi:10.31646/gbio.56 (inactive 26 មេសា 2020)
- Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G (មីនា 2020) "Real estimates of mortality following COVID-19 infection." The Lancet Infectious Diseases doi:10.1016/S1473-3099(20)30195-X PMC 7118515 Check
|pmc=value (ជំនួយ) PMID 32171390 Check
- Vardavas, Constantine I.; Nikitara, Katerina (20 មីនា 2020) "COVID-19 and smoking: A systematic review of the evidence" Tobacco Induced Diseases 18 (March): 20 doi:10.18332/tid/119324 ISSN 1617-9625 PMC 7083240 Check
|pmc=value (ជំនួយ) PMID 32206052 Check
- Cheung E (13 មីនា 2020) "Some recovered Covid-19 patients may have lung damage, doctors say" South China Morning Post បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ15 មីនា 2020 ដកស្រង់នៅថ្ងៃ 15 មីនា 2020 Unknown parameter
- Servick, Kelly (8 មេសា 2020) "For survivors of severe COVID-19, beating the virus is just the beginning" Science doi:10.1126/science.abc1486 ISSN 0036-8075
- "Coronavirus Disease 2019 (COVID-19) DAILY EPIDEMIOLOGY UPDATE Updated: 5 May, 2020, 11:00 AM ET" (PDF) Public Health Agency of Canada 5 ឧសភា 2020 ដកស្រង់នៅថ្ងៃ 6 ឧសភា 2020 Unknown parameter
- (ជាDanish) COVID-19 i Danmark: Epidemiologisk overvågningsrapport den 5. maj 2020 (Report). Statens Serum Institut. 2020-05-05. https://files.ssi.dk/COVID19-overvaagningsrapport-30042020-2h7d។ បានយកមក 2020-05-05.
- "Robert Koch-Institut: COVID-19-Dashboard" Experience.arcgis.com ដកស្រង់នៅថ្ងៃ 7 ឧសភា 2020
- "קורונה - משרד הבריאות" Ministry of Health (Israel) 3 ឧសភា 2020 ដកស្រង់នៅថ្ងៃ 5 ឧសភា 2020
- (ជាItalian) Epidemia COVID-19. Aggiornamento nazionale 28 aprile 2020 (Report). Rome: Istituto Superiore di Sanità. 29 April 2020. https://www.epicentro.iss.it/coronavirus/bollettino/Bollettino-sorveglianza-integrata-COVID-19_28-aprile-2020.pdf។ បានយកមក 30 April 2020.
- "KDPH COVID-19 Dashboard" Kygeonet.maps.arcgis.com ដកស្រង់នៅថ្ងៃ 7 ឧសភា 2020
- "COVID-19 Response Reporting" Mass.gov 1 មករា 2020 ដកស្រង់នៅថ្ងៃ 7 ឧសភា 2020
- (ជាDutch) Epidemiologische situatie COVID-19 in Nederland 25 april 2020 (Report). Bilthoven: Rijksinstituut voor Volksgezondheid en Milie. 25 April 2020. https://www.rivm.nl/documenten/epidemiologische-situatie-covid-19-in-nederland-25-april-2020។ បានយកមក 25 April 2020.
- "NOVO CORONAVÍRUS COVID-19 RELATÓRIO DE SITUAÇÃO" (PDF) (ព័រទុយហ្គាល់) 5 ឧសភា 2020 ដកស្រង់នៅថ្ងៃ 5 ឧសភា 2020
- (ជាko) 코로나바이러스감염증-19 국내 발생 현황(4월 30일, 정례브리핑) (Report). Korea Centers for Disease Control and Prevention. 30 April 2020. https://www.cdc.go.kr/board/board.es?mid=a20501000000&bid=0015&list_no=367051&act=view។ បានយកមក 30 April 2020.
- "FOHM Covid-19" Public Health Agency of Sweden ដកស្រង់នៅថ្ងៃ 5 ឧសភា 2020
- "Todesfälle in der Schweiz nach Altersgruppen" datawrapper.dwcdn.net 30 មេសា 2020 ដកស្រង់នៅថ្ងៃ 30 មេសា 2020
- "2019 Novel Coronavirus Outbreak (COVID-19)" Washington State Department of Health 5 ឧសភា 2020 ដកស្រង់នៅថ្ងៃ 6 ឧសភា 2020
- CDC COVID-19 Response Team (18 មីនា 2020) "Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19)—United States, February 12 – March 16, 2020" Morbidity and Mortality Weekly Report Centers for Disease Control 69 (12): 343–346 doi:10.15585/mmwr.mm6912e2 PMID 32214079 Check
|pmid=value (ជំនួយ) បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ22 មីនា 2020 ដកស្រង់នៅថ្ងៃ 22 មីនា 2020 Unknown parameter
- Verity, Robert; Okell, Lucy C; Dorigatti, Ilaria; Winskill, Peter; Whittaker, Charles; Imai, Natsuko; Cuomo-Dannenburg, Gina; Thompson, Hayley; Walker, Patrick G T; Fu, Han; Dighe, Amy (30 មីនា 2020) "Estimates of the severity of coronavirus disease 2019: a model-based analysis" The Lancet Infectious Diseases doi:10.1016/s1473-3099(20)30243-7 ISSN 1473-3099 PMC 7158570 Check
|pmc=value (ជំនួយ) PMID 32240634 Check
- "BSI open letter to Government on SARS-CoV-2 outbreak response" immunology.org British Society for Immunology បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ14 មីនា 2020 ដកស្រង់នៅថ្ងៃ 15 មីនា 2020 Unknown parameter
- Schraer, Rachel (25 មេសា 2020) "Coronavirus: Immunity passports 'could increase virus spread'" ដកស្រង់នៅថ្ងៃ 26 មេសា 2020
- "Can you get coronavirus twice or does it cause immunity?" The Independent 13 មីនា 2020 បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ14 មីនា 2020 ដកស្រង់នៅថ្ងៃ 15 មីនា 2020 Unknown parameter
- Politi, Daniel (11 មេសា 2020) "WHO Investigating Reports of Coronavirus Patients Testing Positive Again After Recovery" Slate ដកស្រង់នៅថ្ងៃ 11 មេសា 2020
- "They survived the coronavirus. Then they tested positive again. Why?" Los Angeles Times 13 មីនា 2020 បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ14 មីនា 2020 ដកស្រង់នៅថ្ងៃ 15 មីនា 2020 Unknown parameter
- "14% of Recovered Covid-19 Patients in Guangdong Tested Positive Again" caixinglobal.com Caixin Global បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ3 មីនា 2020 ដកស្រង់នៅថ្ងៃ 15 មីនា 2020 Unknown parameter
- Omer, SB; Malani, P; del Rio, C (6 មេសា 2020) "The COVID-19 Pandemic in the US A Clinical Update" JAMA doi:10.1001/jama.2020.5788 PMID 32250388 Check
- Richard Lloyd Parry (30 April 2020), "Coronavirus patients can't relapse, South Korean scientists believe", The Times, https://www.thetimes.co.uk/article/coronavirus-patients-cant-relapse-south-korean-scientists-believe-rkm8zm7d9
- "What if immunity to covid-19 doesn't last?" MIT Technology Review (អង់គ្លេស) ដកស្រង់នៅថ្ងៃ 1 ឧសភា 2020
- "Direct observation of repeated infections with endemic coronaviruses" (PDF) Columbia University in the City of New York (អង់គ្លេស) Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University 15 មេសា 2020 ដកស្រង់នៅថ្ងៃ 2 ឧសភា 2020
- Berger K (12 មីនា 2020) "The Man Who Saw the Pandemic Coming" Nautilus បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ15 មីនា 2020 ដកស្រង់នៅថ្ងៃ 16 មីនា 2020 Unknown parameter
- Heymann DL, Shindo N (កុម្ភៈ 2020) "COVID-19: what is next for public health?" Lancet 395 (10224): 542–45 doi:10.1016/S0140-6736(20)30374-3 PMID 32061313 Check
- Wu, Yi-Chi; Chen, Ching-Sung; Chan, Yu-Jiun (មីនា 2020) "The outbreak of COVID-19: An overview" Journal of the Chinese Medical Association 83 (3): 217–220 doi:10.1097/JCMA.0000000000000270 ISSN 1726-4901 PMC 7153464 Check
|pmc=value (ជំនួយ) PMID 32134861 Check
- Wang, C.; Horby, P. W.; Hayden, F. G.; Gao, G. F. (កុម្ភៈ 2020) "A novel coronavirus outbreak of global health concern" Lancet 395 (10223): 470–473 doi:10.1016/S0140-6736(20)30185-9 PMC 7135038 Check
|pmc=value (ជំនួយ) PMID 31986257
- Cohen, Jon (មករា 2020) "Wuhan seafood market may not be source of novel virus spreading globally" Science doi:10.1126/science.abb0611
- "Novel Coronavirus—China" World Health Organization (WHO) 12 មករា 2020
- Kessler G (17 មេសា 2020) "Trump's false claim that the WHO said the coronavirus was 'not communicable'" The Washington Post បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ17 មេសា 2020 ដកស្រង់នៅថ្ងៃ 17 មេសា 2020 Unknown parameter
- Kuo, Lily (21 មករា 2020) "China confirms human-to-human transmission of coronavirus" The Guardian ដកស្រង់នៅថ្ងៃ 18 មេសា 2020
- "Principles of Epidemiology | Lesson 3—Section 3" www.cdc.gov 18 កុម្ភៈ 2019 បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ28 កុម្ភៈ 2020 ដកស្រង់នៅថ្ងៃ 28 មីនា 2020 Unknown parameter
- Ritchie, Hannah; Roser, Max (25 មីនា 2020) Chivers, Tom (ed.) "What do we know about the risk of dying from COVID-19?" Our World in Data បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ28 មីនា 2020 ដកស្រង់នៅថ្ងៃ 28 មីនា 2020 Unknown parameter
- Lazzerini, Marzia; Putoto, Giovanni (18 មីនា 2020) "COVID-19 in Italy: momentous decisions and many uncertainties" The Lancet Global Health 0 (5): e641–e642 doi:10.1016/S2214-109X(20)30110-8 ISSN 2214-109X PMC 7104294 Check
|pmc=value (ជំនួយ) PMID 32199072 Check
- "What do we know about the risk of dying from COVID-19?" Our World in Data បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ28 មីនា 2020 ដកស្រង់នៅថ្ងៃ 28 មីនា 2020 Unknown parameter
- Hawks, L; Woolhandler, S; McCormick, D (មេសា 2020) "COVID-19 in Prisons and Jails in the United States." JAMA Internal Medicine doi:10.1001/jamainternmed.2020.1856 PMID 32343355 Check
- "Total confirmed cases of COVID-19 per million people" Our World in Data បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ19 មីនា 2020 ដកស្រង់នៅថ្ងៃ 10 មេសា 2020 Unknown parameter
- "Total confirmed deaths due to COVID-19 per million people" Our World in Data បណ្ណសារចម្លងពីខ្លឹមសារដើមនៅ19 មីនា 2020 ដកស្រង់នៅថ្ងៃ 10 មេសា 2020 Unknown parameter
- "What do we know about the risk of dying from COVID-19?" Our World in Data ដកស្រង់នៅថ្ងៃ 23 មេសា 2020
- "Coronavirus disease 2019 (COVID-19) Situation Report—31" (PDF) 20 កុម្ភៈ 2020 ដកស្រង់នៅថ្ងៃ 23 មេសា 2020
- "Global Covid-19 Case Fatality Rates" Centre for Evidence-Based Medicine 17 មីនា 2020 ដកស្រង់នៅថ្ងៃ 10 មេសា 2020 Unknown parameter
- Haake, Daniel (24 មេសា 2020) "Gangelt — A representative study on the lethality of COVID-19" Medium ដកស្រង់នៅថ្ងៃ 27 មេសា 2020
- VogelApr. 21, Gretchen; 2020; Pm, 6:30 (21 មេសា 2020) "Antibody surveys suggesting vast undercount of coronavirus infections may be unreliable" Science | AAAS ដកស្រង់នៅថ្ងៃ 29 មេសា 2020
- Modi, Chirag (21 មេសា 2020) "How deadly is COVID-19? Data Science offers answers from Italy mortality data." Medium ដកស្រង់នៅថ្ងៃ 23 មេសា 2020
- Modi, Chirag; Boehm, Vanessa; Ferraro, Simone; Stein, George; Seljak, Uros (20 មេសា 2020) "Total COVID-19 Mortality in Italy: Excess Mortality and Age Dependence through Time-Series Analysis" MedRxiv: 2020.04.15.20067074 doi:10.1101/2020.04.15.20067074
- Wu J, McCann A, Katz J, Peltier E (27 មេសា 2020) "36,000 Missing Deaths: Tracking the True Toll of the Coronavirus Crisis" The New York Times ISSN 0362-4331 ដកស្រង់នៅថ្ងៃ 27 មេសា 2020 Unknown parameter
- "The Coronavirus Isn't Just the Flu, Bro" www.bloomberg.com ដកស្រង់នៅថ្ងៃ 26 មេសា 2020